Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome

ABSTRACT

The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS.

CROSS REFERENCE TO RELATED APPLICATIONS

This patent application claims priority pursuant to 35 U.S.C. § 119(e)to U.S. Provisional Patent Application No. 62/371,030, filed Aug. 4,2016, which is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

The disclosure relates to a method for treating sickle cell disease withA Disintegrin And Metalloproteinase with Thrombospondin type 1 motif,member-13 (ADAMTS13). More particularly, the disclosure relates to amethod for treating, ameliorating, and/or preventing vaso-occlusivecrisis (VOC) in a subject with sickle cell disease (SCD) byadministering ADAMTS13. The disclosure includes uses of ADAMTS13 and/orcompositions comprising ADAMTS13 for the preparation of medicaments forthe treatment, amelioration, and/or prevention of VOC in SCD. Thedisclosure also relates to a method for treating, ameliorating, orpreventing lung injury in a subject suffering from or at risk ofsuffering from acute lung injury (ALI) and/or acute respiratory distresssyndrome (ARDS) with ADAMTS13, and uses of ADAMTS13 and/or compositionscomprising ADAMTS13 for the preparation of medicaments for thetreatment, amelioration, and/or prevention of ALI and/or ARDS.

BACKGROUND OF THE INVENTION

Sickle cell disease (SCD) is a worldwide distributed hereditary redblood cell disorder, which results from a point mutation (β^(s), 6V) inthe β-globin chain leading to the production of a defective form ofhemoglobin, hemoglobin S (HbS). Studies of the kinetics of HbSpolymerization following deoxygenation have shown it to be a high orderexponential function of hemoglobin concentration, thus highlighting acrucial role for cellular HbS concentration in sickling.Pathophysiological studies have shown that the dense, dehydrated redblood cells play a central role in acute and chronic clinicalmanifestations of SCD, in which intravascular sickling in capillaries,small vessels, and large vessels leads to vaso-occlusion and impairedblood flow with ischemic cell damage in a variety of organs and tissues.

In SCD patients, increased levels of von Willebrand factor (VWF) and ofultra-large VWF multimers have been observed and are associated withacute vaso-occlusive events. The levels of ultra-large VWF multimers aredependent on the activity of the metalloprotease A Disintegrin AndMetalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13)that cleaves the hyperadhesive ultra-large VWF multimers underconditions of high fluid shear stress, playing an important role inmaintaining a proper balance of hemostatic activity and thrombotic risk.ADAMTS13 cleaves VWF between residues Tyr¹⁶⁰⁵ and Met¹⁶⁰⁶, whichcorresponds to residues 842-843 after cleavage of the preprosequence. Itis this ADAMTS13-mediated cleavage of VWF that is largely responsiblefor modulation of VWF multimeric size and hemostatic activity. VWFreleased through stimulation or circulating in blood is important informing platelet thrombi because it plays a role with collagen onplatelet adhesion and agglutination in subendothelial tissue, includingdamaged vascular walls. VWF release is accompanied and partly triggeredby activation of the vascular endothelium. Thus, biomarkers of vascularinflammation provide additional information on the risk ofvaso-occlusive events.

Extracellular hemoglobin (ECHb) is increased in SCD patients andinhibits ADAMTS13-mediated VWF proteolysis by binding to the A2 domainof VWF particularly to the ADAMTS13 cleavage site. Thrombospondin-1(TSP1), which is also increased in patients with SCD, binds to the A2domain of ultra-large VWF multimers and also prevents VWF degradation byADAMTS13 by competitively inhibiting ADAMTS13 activity.

SCD is a congenital, life-long illness. People with SCD inherit twoabnormal hemoglobin β^(S) genes, one from each parent. When a person hastwo hemoglobin S genes, Hemoglobin SS (Hb SS), the disease is calledsickle cell anemia. This is the most common and often most severe kindof SCD. Hemoglobin SC disease and hemoglobin Sβ thalassemia are twoother common forms of SCD. In all forms of SCD, at least one of the twoabnormal genes causes a person's body to make hemoglobin S or sicklehemoglobin, in their red blood cells. Hemoglobin is a protein in redblood cells that carries oxygen throughout the body. Sickle hemoglobindiffers from normal hemoglobin in its propensity to form polymers underconditions of low oxygen tension, which form stiff rods within the redblood cell, changing it into a crescent, or sickle shape. Sickle-shapedcells are not flexible, which can cause a blockage that slows or stopsthe flow of blood and essentially obstructs the microcirculation. Whenthis happens, oxygen cannot reach nearby tissues. The lack of tissueoxygen can cause attacks of sudden, severe pain, called vaso-occlusivecrisis (VOC), pain crisis, or sickle cell crisis, which results inischemic injury to the organ supplied and resultant pain. Pain crisesconstitute the most distinguishing clinical feature of VOC of SCD andare the leading cause of emergency department visits andhospitalizations for affected patients.

VOC is initiated and sustained by interactions among sickle cells,including sickle cell reticulocytes, endothelial cells, leukocytes, andplasma constituents, including VWF. Vaso-occlusion is responsible for awide variety of clinical complications of SCD, including pain syndromes,stroke, leg ulcers, spontaneous abortion and renal insufficiency. Thepain of VOC is often incompletely treated. Current treatment of VOCincludes, among other things, the use of fluids, oxygen, and analgesia,while the incidence of VOC may be reduced with chronic red blood cell(RBC) transfusion as well as hydroxyurea. Despite advances in painmanagement, however, physicians are often reluctant to give patientsadequate dosages of narcotic analgesics because of concerns aboutaddiction, tolerance and side effects. In addition to acute VOC, otheracute and chronic complications of SCD include renal disease, splenicinfarction, increased risk of bacterial infection, acute and chronicanemia, chest syndrome, stroke and ocular disease.

Acute pain in patients with SCD is caused by ischemic tissue injuryresulting from the occlusion of microvascular beds by sicklederythrocytes during an acute crisis. For example, the severe bone painthat is characteristic of VOC is believed to be caused by increasedintra-medullary pressure, especially within the juxta-articular areas oflong bones, secondary to an acute inflammatory response to vascularnecrosis of the bone marrow by sickled erythrocytes. The pain may alsooccur because of involvement of the periosteum or periarticular softtissue of the joints. The effect of unpredictable recurrences of acutecrises on chronic pain creates a unique pain syndrome.

The severity of SCD varies widely from person to person. Advances in thediagnosis and care of SCD have extended the life expectancies of personswith SCD. In high-income countries like the United States, the lifeexpectancy of a person with SCD is now about 40-60 years, whereas it wasonly 14 years about 40 years ago. At the present time, however,hematopoietic stem cell transplantation (HSCT) is the only cure for SCD.Unfortunately, most people with SCD are either too old for a transplantor do not have a relative who is a good enough genetic match for them toact as a donor for a successful transplant. Thus, there is a need in theart for improved treatments of SCD, including the treatment ofvaso-occlusive events of SCD that can reduce symptoms, preventcomplications, and improve length and quality of life.

SUMMARY OF THE INVENTION

The disclosure includes a method for treating, ameliorating, and/orpreventing a vaso-occlusive crisis (VOC) in a subject suffering fromsickle cell disease (SCD), wherein the method comprises administering tothe subject in need thereof a therapeutically effective amount of acomposition comprising ADAMTS13.

The disclosure includes a method for treating, ameliorating, and/orpreventing a lung injury in a subject suffering from acute lung injury(ALI) and/or acute respiratory distress syndrome (ARDS), wherein themethod comprises administering to the subject in need thereof atherapeutically effective amount of a composition comprising ADAMTS13.

The disclosure includes uses of ADAMTS13 and/or compositions comprisingADAMTS13 for the preparation of medicaments. Other related aspects arealso provided in the disclosure.

The disclosure provides a method for treating, ameliorating, and/orpreventing a VOC in a subject suffering from SCD, the method comprisingadministering to the subject in need thereof a therapeutically effectiveamount of a composition comprising ADAMTS13. In some embodiments, thesubject is treated after symptoms of a VOC are present. In someembodiments, the subject is treated before symptoms of a VOC crisis arepresent. In some embodiments, treating reduces at least one ofinflammation, vasoconstriction, or platelet aggregation, or acombination of any thereof. In some embodiments, treating results in atleast one of improved survival, improved lung function, or reduced organdamage, reduced pulmonary vascular leakage, or a combination of anythereof. In some embodiments, treating reduces and/or prevents at leastone of impaired blood flow (e.g., ischemia), blood coagulation, vascularinflammation, thrombosis, ischemic cell damage, or organ damage, or acombination of any thereof. In some embodiments, treating reduces and/orprevents pain or severity of the pain. In some embodiments, treatingreduces the frequency of occurrence of VOC and/or duration of VOCepisodes. In certain embodiments, administration of ADAMTS13 results inreduced expression, level, and/or activation of at least one of VCAM-1,ICAM-1, P-NF-kB/NF-kB ratio, ET-1, TXAS, and HO-1 in an organ. In someembodiments, the comparison is to a control subject. In someembodiments, the comparison is to measurements taken prior to treatment.

In certain embodiments, organs include, but are not limited to, lung,liver, pancreas, skin, retina, prostate, ovary, lymph node, adrenalgland, kidney, heart, gallbladder or GI track. In some embodiments,organ tissue includes, but is not limited to the lungs, liver, spleen,and/or kidneys. In certain embodiments, the organ is a lung. In certainembodiments, the organ is a kidney.

In certain embodiments, administration of ADAMTS13 results in anincrease of at least one of Hct, Hb, MCV, and MCH levels in the bloodand/or a reduction in at least one of CHCM, HDW, LDH, and neutrophilnumbers in the blood as compared to control.

In some aspects of the disclosure, the therapeutically effective amountof ADAMTS13 for treating, ameliorating, or preventing a VOC in a subjectsuffering from SCD is from about 20 to about 6,000 international unitsper kilogram body weight. In some aspects, the therapeutically effectiveamount is from about 40 to about 4,000 international units per kilogrambody weight. In some aspects, the therapeutically effective amount isfrom about 100 to about 3,000 international units per kilogram bodyweight. In some aspects, the therapeutically effective amount is fromabout 50 to about 500 international units per kilogram body weight.

In particular aspects, the dosage or therapeutically effective amountfor treating, ameliorating, or preventing a VOC in a subject sufferingfrom SCD is from about 10 to about 500 international units per kilogrambody weight. In some aspects, the dosage or therapeutically effectiveamount is from about 50 to about 450 international units per kilogrambody weight. In some aspects, the therapeutically effective amount isfrom about 40 to about 150 international units per kilogram body weight.In some aspects, the therapeutically effective amount is from about 100to about 500 international units per kilogram body weight. In someaspects, the dosage or therapeutically effective amount is from about100 to about 400 international units per kilogram body weight. In someaspects, the therapeutically effective amount is from about 100 to about300 international units per kilogram body weight. In some aspects, thetherapeutically effective amount is from about 300 to about 500international units per kilogram body weight. In some aspects, thedosage or therapeutically effective amount is from about 200 to about300 international units per kilogram body weight. In some aspects, thedosage or therapeutically effective amount is about 100, about 150,about 200, about 250, about 300, about 350, about 400, about 450, orabout 500 international units per kilogram body weight.

In further aspects, the dosage or therapeutically effective amount fortreating, ameliorating, or preventing a VOC in a subject suffering fromSCD is from about 50 to about 1,000 international units per kilogrambody weight. In some aspects, the dosage or therapeutically effectiveamount is from about 100 to about 900 international units per kilogrambody weight. In some aspects, the dosage or therapeutically effectiveamount is from about 200 to about 800 international units per kilogrambody weight. In some aspects, the dosage or therapeutically effectiveamount is from about 300 to about 700 international units per kilogrambody weight. In some aspects, the dosage or therapeutically effectiveamount is from about 400 to about 600 international units per kilogrambody weight. In some aspects, the dosage or therapeutically effectiveamount is about 500 international units per kilogram body weight.

In some embodiments, the composition comprising ADAMTS13, for treating,ameliorating, or preventing a VOC in a subject suffering from SCD, isadministered in a single bolus injection, monthly, every two weeks,weekly, twice a week, daily, every 12 hours, every eight hours, everysix hours, every four hours, or every two hours. In some embodiments,the composition comprising ADAMTS13 is administered intravenously orsubcutaneously. In some embodiments, the composition comprising ADAMTS13is administered intravenously. In some embodiments, the compositioncomprising ADAMTS13 is administered subcutaneously.

In some aspects of the disclosure, the therapeutically effective amountof the composition comprising ADAMTS13 is administered to the subjectwithin 48 hours after the onset of the VOC. In some aspects, thetherapeutically effective amount of the composition comprising ADAMTS13is administered to the subject within 24 hours after the onset of theVOC. In some aspects, the therapeutically effective amount of thecomposition comprising ADAMTS13 is administered to the subject within 12hours after the onset of the VOC. In some aspects, the therapeuticallyeffective amount of the composition comprising ADAMTS13 is administeredto the subject within 6 hours after the onset of the VOC.

In some aspects of the disclosure, the therapeutically effective amountof the composition comprising ADAMTS13 for preventing the VOC issufficient to maintain an effective level of ADAMTS13 activity in thesubject. In some aspects, the therapeutically effective amount of thecomposition comprising ADAMTS13 for preventing the VOC is administeredmonthly, biweekly, weekly, or twice a week to prevent a VOC. In someembodiments the administering is subcutaneous. In some aspects, theadministering is intravenous.

The disclosure includes the use of a composition comprising ADAMTS13 fortreating or preventing a VOC in a subject suffering from SCD. In someembodiments, the disclosure includes a composition comprising ADAMTS13for use as a medicament for the treatment or prevention of a VOC in asubject suffering from SCD.

In certain embodiments, the methods of treating or preventing VOCcomprises (i) administering ADAMTS13 and (ii) evaluating whether aparameter or symptom has changed, wherein the parameter is selected fromthe group consisting of inflammation, vasoconstriction, plateletaggregation, lung function, organ (e.g., lung or kidney) damage,pulmonary vascular leakage, blood flow, blood coagulation, vascularinflammation, thrombosis, ischemic cell damage, presence of pain,severity of pain, frequency of occurrence of VOC, duration of VOCepisodes, VCAM-1, ICAM-1, P-NF-kB/NF-kB ratio, ET-1, TXAS, HO-1, Hct,Hb, MCV, HDW, reticulocyte numbers, and neutrophil numbers.

The disclosure also provides a method for treating, ameliorating, and/orpreventing lung injury in a subject suffering from or at risk ofsuffering from ALI and/or ARDS, the method comprising administering tothe subject in need thereof a therapeutically effective amount of acomposition comprising ADAMTS13. In some aspects, the subject suffersfrom a condition or a combination of the conditions selected from thegroup consisting of inflammatory pulmonary edema, inflammatory pulmonaryinfiltrates, impaired oxygenation, and hypoxemia. In some aspects,treating results in at least one of improved survival, improved lungfunction, or reduced organ damage, reduced pulmonary vascular leakage,or a combination of any thereof. In some aspects, treating reduces atleast one of inflammation, vasoconstriction, or platelet aggregation, ora combination of any thereof. In some aspects, treating reduces and/orprevents at least one of impaired blood flow (e.g., ischemia), bloodcoagulation, vascular inflammation, thrombosis, ischemic cell damage, ororgan damage, or a combination of any thereof. In some aspects, treatingreduces and/or prevents pain or severity of the pain. In someembodiments, treating reduces the frequency of occurrence or ALI and/orARDS and/or duration of ALI and/or ARDS episodes. In certainembodiments, administration of ADAMTS13 results in reduced expression,level, and/or activation of at least one of VCAM-1, ICAM-1,P-NF-kB/NF-kB ratio, ET-1, TXAS, and HO-1 in an organ. In someembodiments, the comparison is to a control subject. In someembodiments, the comparison is to measurements taken prior to treatment.

In certain embodiments, organs include, but are not limited to, lung,liver, pancreas, skin, retina, prostate, ovary, lymph node, adrenalgland, kidney, heart, gallbladder or GI track. In some embodiments,organ tissue includes, but is not limited to the lungs, liver, spleen,and/or kidneys. In certain embodiments, the organ is a lung. In certainembodiments, the organ is a kidney.

In certain embodiments, administration of ADAMTS13 results in areduction in neutrophil numbers in the blood as compared to control.

In some aspects of the disclosure, the therapeutically effective amountof ADAMTS13 for treating, ameliorating, or preventing lung injury in asubject suffering from or at risk of suffering from ALI and/or ARDS isfrom about 20 to about 6,000 international units per kilogram bodyweight. In some aspects, the therapeutically effective amount is fromabout 40 to about 4,000 international units per kilogram body weight. Insome aspects, the therapeutically effective amount is from about 100 toabout 3,000 international units per kilogram body weight. In someaspects, the therapeutically effective amount is from about 50 to about500 international units per kilogram body weight.

In particular aspects, the dosage or therapeutically effective amountfor treating, ameliorating, or preventing lung injury in a subjectsuffering from or at risk of suffering from ALI and/or ARDS is fromabout 10 to about 500 international units per kilogram body weight. Insome aspects, the dosage or therapeutically effective amount is fromabout 50 to about 450 international units per kilogram body weight. Insome aspects, the therapeutically effective amount is from about 40 toabout 150 international units per kilogram body weight. In some aspects,the therapeutically effective amount is from about 100 to about 500international units per kilogram body weight. In some aspects, thedosage or therapeutically effective amount is from about 100 to about400 international units per kilogram body weight. In some aspects, thetherapeutically effective amount is from about 100 to about 300international units per kilogram body weight. In some aspects, thetherapeutically effective amount is from about 300 to about 500international units per kilogram body weight. In some aspects, thedosage or therapeutically effective amount is from about 200 to about300 international units per kilogram body weight. In some aspects, thedosage or therapeutically effective amount is about 100, about 150,about 200, about 250, about 300, about 350, about 400, about 450, orabout 500 international units per kilogram body weight.

In further aspects, the dosage or therapeutically effective amount fortreating, ameliorating, or preventing lung injury in a subject sufferingfrom or at risk of suffering from ALI and/or ARDS is from about 50 toabout 1,000 international units per kilogram body weight. In someaspects, the dosage or therapeutically effective amount is from about100 to about 900 international units per kilogram body weight. In someaspects, the dosage or therapeutically effective amount is from about200 to about 800 international units per kilogram body weight. In someaspects, the dosage or therapeutically effective amount is from about300 to about 700 international units per kilogram body weight. In someaspects, the dosage or therapeutically effective amount is from about400 to about 600 international units per kilogram body weight. In someaspects, the dosage or therapeutically effective amount is about 500international units per kilogram body weight.

In some embodiments, the therapeutically effective amount of thecomposition comprising ADAMTS13, for treating, ameliorating, and/orpreventing lung injury in a subject suffering from or at risk ofsuffering from ALI and/or ARDS, is administered to the subject within 48hours after the detection of inflammatory pulmonary edema, inflammatorypulmonary infiltrates, impaired oxygenation, or hypoxemia. In someembodiments, the therapeutically effective amount of the compositioncomprising ADAMTS13 is administered to the subject within 24 hours afterthe detection of inflammatory pulmonary edema, inflammatory pulmonaryinfiltrates, impaired oxygenation, or hypoxemia. In some embodiments,the therapeutically effective amount of the composition comprisingADAMTS13 is administered to the subject within 12 hours after thedetection of inflammatory pulmonary edema, inflammatory pulmonaryinfiltrates, impaired oxygenation, or hypoxemia. In some embodiments,the therapeutically effective amount of the composition comprisingADAMTS13 is administered to the subject within 6 hours after thedetection of inflammatory pulmonary edema, inflammatory pulmonaryinfiltrates, impaired oxygenation, or hypoxemia.

In some embodiments, the composition comprising ADAMTS13 is administeredin a single bolus injection, monthly, every two weeks, weekly, twice aweek, daily, every 12 hours, every eight hours, every six hours, everyfour hours, or every two hours. In some embodiments, the compositioncomprising ADAMTS13 is administered intravenously or subcutaneously. Insome embodiments, the composition comprising ADAMTS13 is administeredintravenously. In some embodiments, the composition comprising ADAMTS13is administered subcutaneously.

In various aspects of the disclosure, ADAMTS13 is recombinant ADAMTS13.In some aspects, ADAMTS13 is plasma derived.

In various aspects of the disclosure, the subject is a mammal. In someaspects the subject is a human.

In some aspects, the composition is in a stable aqueous solution readyfor administration.

In some aspects, the therapeutically effective amount of the compositioncomprising ADAMTS13 for treating, ameliorating, and/or preventing lunginjury is sufficient to maintain an effective circulating level ofADAMTS13 activity in the subject.

The disclosure includes the use of a composition comprising ADAMTS13 fortreating, ameliorating and/or preventing lung injury in a subjectsuffering from or at risk of suffering from ALI and/or ARDS. In someaspects, the subject is suffering from ALI. In some aspects, the subjectis suffering from ARDS.

The disclosure also includes a composition comprising ADAMTS13 for useas a medicament for the treatment, amelioration, or prevention of a lunginjury in a subject suffering from or at risk of suffering from ALIand/or ARDS.

In certain embodiments, the methods of treating or preventing ALI/ARDScomprises (i) administering ADAMTS13 and (ii) evaluating whether aparameter or symptom has changed, wherein the parameter is selected fromthe group consisting of inflammation, vasoconstriction, plateletaggregation, lung function, organ (e.g., lung or kidney) damage,pulmonary vascular leakage, blood flow, blood coagulation, vascularinflammation, thrombosis, ischemic cell damage, frequency of occurrenceof ALI/ARDS, duration of ALI/ARDS episodes, VCAM-1, ICAM-1,P-NF-kB/NF-kB ratio, ET-1, TXAS, HO-1, Hct, Hb, MCV, HDW, reticulocytenumbers, and neutrophil numbers.

The foregoing summary is not intended to define every aspect of theinvention, and additional aspects are described in other sections, suchas the following detailed description. The entire document is intendedto be related as a unified disclosure, and it should be understood thatall combinations of features described herein are contemplated, even ifthe combination of features are not found together in the same sentence,or paragraph, or section of this document. Other features and advantagesof the invention will become apparent from the following detaileddescription. It should be understood, however, that the detaileddescription and the specific examples, while indicating specificembodiments of the invention, are given by way of illustration only,because various changes and modifications within the spirit and scope ofthe invention will become apparent to those skilled in the art from thisdetailed description.

DESCRIPTION OF THE FIGURES

FIG. 1 is a graph showing that ADAMTS13 protects sickle cell mice (SCD)from death related to a severe acute VOC. Mice (n=6) were treated withrADAMTS13 (BAX930/SHP655 (2,940 FRETS-U/kg (3,200 IU/kg))) and exposedto 7% oxygen for 10 h followed by 3 h recovery at 21% oxygen. Survivalcurves for rADAMTS13-treated SCD mice, vehicle-treated AA (healthy)mice, and ADAMTS13-treated AA mice, were significantly different(p<0.001) from those of vehicle-treated SCD mice. After 13 hours, noanimals survived in the group of vehicle-treated SCD mice, whereas 100%of the animals in all of the other three groups survived.

FIG. 2A-2C: FIG. 2A shows that SCD (SS) mice had a significantly greaternumber of leukocytes and significantly more protein content inbronchoalveolar lavage compared to controls, indicating vascularleakage. Treatment with rADAMTS13 (BAX930/SHP655) markedly reduced thiseffect, indicating a reduction of systemic inflammation and ofabnormalities in pulmonary vascular dysfunction. FIG. 2B shows thatrADAMTS13 (BAX930/SHP655) prevented the hypoxia-induced activation ofNF-kB in lungs of AA and SCD mice, indicating that ADAMTS13 decreasesthe pulmonary inflammation process triggered by hypoxia. FIG. 2C showsthat rADAMTS13 (BAX930/SHP655) prevented activation of various markersof vascular activation and inflammatory vasculopathy in the lungs of SCDmice after exposure to hypoxic conditions.

FIG. 3A-B: FIG. 3A shows that rADAMTS13 (BAX930/SHP655) prevented thehypoxia-induced activation of NF-kB in kidneys of AA and SCD mice, aswell as of SCD mice under normoxic conditions, indicating that ADAMTS13decreases the inflammation process triggered by hypoxia in the kidneysas well as the lungs. FIG. 3B shows that rADAMTS13 (BAX930/SHP655)prevented activation of various markers of vascular activation andinflammatory vasculopathy in the kidneys of SCD mice after exposure tohypoxic conditions.

DETAILED DESCRIPTION OF THE INVENTION

The disclosure provides, in various aspects, ADAMTS13 for preventing,ameliorating, and/or treating a VOC in SCD. Before any embodiments ofthe disclosure are explained in detail, it is to be understood that theinvention is not limited in its application to the details ofconstruction and the arrangement of components set forth in thefollowing description or illustrated in the figures and examples. Thesection headings used herein are for organizational purposes only andare not to be construed as limiting the subject matter described. Allreferences cited in this application are expressly incorporated byreference herein for all purposes.

The disclosure embraces other embodiments and is practiced or carriedout in various ways. Also, it is to be understood that the phraseologyand terminology used herein is for the purpose of description and shouldnot be regarded as limiting. The terms “including,” “comprising,” or“having” and variations thereof are meant to encompass the items listedthereafter and equivalents thereof as well as additional items.

The following abbreviations are used throughout.

AA mice Transgenic mice homozygous for Hemoglobin A (HbA)

ADAMTS A Disintegrin And Metalloproteinase with Thrombospondin

ADAMTS13 A Disintegrin And Metalloproteinase with Thrombospondin type 1motif, member-13

ALI Acute lung injury

ARDS Acute respiratory distress syndrome

BAL Bronchoalveolar lavage

DNA Deoxyribonucleic acid

ET-1 Endothelin 1

FRETS U FRETS units

GAPDH Glyceraldehyde 3-phosphate dehydrogenase

HbA Hemoglobin A

HbS Sickle hemoglobin

HO-1 Heme-oxygenase 1

H/R Hypoxia/Reoxygenation

ICAM-1 Intercellular Adhesion Molecule 1

IU International Units

kDa KiloDalton

LDH Lactate dehydrogenase

NF-kB Nuclear Factor-kappa B

P-NF-kB Phospho-Nuclear Factor-kappa B

rADAMTS13 recombinant ADAMTS13

RBC Red blood cell

RNA Ribonucleic acid

SCD Sickle Cell Disease

SS mice Transgenic mice homozygous for HbS

TXAS Thromboxane synthase

VCAM-1 Vascular Cell Adhesion Molecule-1

VOC Vaso-occlusive crisis

VWF von Willebrand factor

It is noted here that, as used in this specification and the appendedclaims, the singular forms “a,” “an,” and “the” include plural referenceunless the context clearly dictates otherwise. With respect to aspectsof the disclosure described as a genus, all individual species areconsidered separate aspects of the disclosure. If aspects of thedisclosure are described as “comprising” a feature, embodiments also arecontemplated “consisting of” or “consisting essentially of” the feature.

As used herein, the following terms have the meanings ascribed to themunless specified otherwise.

The term “sickle cell disease (SCD),” as used herein, describes a groupof inherited red blood cell disorders that exists in multiple forms.Some forms of SCD are Hemoglobin SS, Hemoglobin SC, Hemoglobin Sβ⁰thalassemia, Hemoglobin Sβ⁺ thalassemia, Hemoglobin SD, and HemoglobinSE. Although Hemoglobin SC disease and hemoglobin β thalassemia are twocommon forms of SCD, the disclosure relates to and includes all forms ofSCD.

The term “vaso-occlusive crisis (VOC),” as used herein, is an attack ofsudden severe pain, which can occur without warning. VOC, also known aspain crisis or sickle cell crisis, is a common painful complication ofSCD in adolescents and adults. VOC is initiated and sustained byinteractions among sickle cells, endothelial cells and plasmaconstituents. Vaso-occlusion is responsible for a wide variety ofclinical complications of SCD, including pain syndromes, stroke, legulcers, spontaneous abortion, and/or renal insufficiency.

The terms “acute lung injury” (ALI) and “acute respiratory distresssyndrome” (ARDS) describe clinical syndromes of acute respiratoryfailure with substantial morbidity and mortality (Johnson et al., J.Aerosol Med. Pulmon. Drug Deliv. 23:243-52, 2010). Both ALI and the moresevere ARDS represent a spectrum of lung disease characterized by thesudden onset of inflammatory pulmonary edema secondary to myriad localor systemic insults, including bilateral, inflammatory pulmonaryinfiltrates and impaired oxygenation or hypoxemia (Walkey et al.,Clinical Epidemiology 4:159-69, 2012). Although ALI and ARDS are twoclinical syndromes of lung injury or disease, the disclosure relates toand includes the use of ADAMTS13 in treating, preventing, orameliorating, not only ALI and ARDS, but all forms of lung injury andlung disease, especially lung disease associated with impairedoxygenation.

“A disintegrin and metalloproteinase with a thrombospondin type 1 motif,member 13 (ADAMTS13)” is also known as von Willebrand factor-cleavingprotease (VWFCP). The term “ADAMTS13” or “ADAMTS13 protein,” as usedherein, includes ADAMTS13 analogs, variants, derivatives (includingchemically-modified derivatives) and fragments thereof. In some aspects,the analogs, variants, derivatives, and fragments thereof have increasedbiological activity compared to ADAMTS13. In various aspects, ADAMTS13is recombinant ADAMTS13 (rADAMTS13) or is blood-derived ADAMTS13,including plasma- and serum-derived ADAMTS13.

As used herein, an “analog” refers to a polypeptide, e.g., ADAMTS13,substantially similar in structure and having the same biologicalactivity, albeit in certain instances to a differing degree, to anaturally-occurring molecule. Analogs differ in the composition of theiramino acid sequences compared to the naturally-occurring polypeptidefrom which the analog is derived, based on one or more mutationsinvolving (i) deletion of one or more amino acid residues at one or moretermini of the polypeptide (including fragments as described above)and/or one or more internal regions of the naturally-occurringpolypeptide sequence, (ii) insertion or addition of one or more aminoacids at one or more termini (typically an “addition” analog) of thepolypeptide and/or one or more internal regions (typically an“insertion” analog) of the naturally-occurring polypeptide sequence or(iii) substitution of one or more amino acids for other amino acids inthe naturally-occurring polypeptide sequence. Substitutions areconservative or non-conservative based on the physico-chemical orfunctional relatedness of the amino acid that is being replaced and theamino acid replacing it.

“Conservatively modified analogs” applies to both amino acid and nucleicacid sequences. With respect to particular nucleic acid sequences,conservatively modified nucleic acids refers to those nucleic acidswhich encode identical or essentially identical amino acid sequences, orwhere the nucleic acid does not encode an amino acid sequence, toessentially identical sequences. Because of the degeneracy of thegenetic code, a large number of functionally identical nucleic acidsencode any given protein. For instance, the codons GCA, GCC, GCG and GCUall encode the amino acid alanine. Thus, at every position where analanine is specified by a codon, the codon can be altered to any of thecorresponding codons described without altering the encoded polypeptide.Such nucleic acid variations are “silent variations,” which are onespecies of conservatively modified analogs. Every nucleic acid sequenceherein which encodes a polypeptide also describes every possible silentvariation of the nucleic acid. One of skill will recognize that eachcodon in a nucleic acid (except AUG, which is ordinarily the only codonfor methionine, and TGG, which is ordinarily the only codon fortryptophan) can be modified to yield a functionally identical molecule.Accordingly, each silent variation of a nucleic acid which encodes apolypeptide is implicit in each described sequence.

As to amino acid sequences, one of skill will recognize that individualsubstitutions, insertions, deletions, additions, or truncations to anucleic acid, peptide, polypeptide, or protein sequence which alters,adds or deletes a single amino acid or a small percentage of amino acidsin the encoded sequence is a “conservatively modified analog” where thealteration results in the substitution of an amino acid with achemically similar amino acid. Conservative substitution tablesproviding functionally similar amino acids are well known in the art.Such conservatively modified variants are in addition to and do notexclude polymorphic variants, interspecies homologs, and alleles of thedisclosure.

The following eight groups each contain amino acids that areconservative substitutions for one another:

-   1) Alanine (A), Glycine (G);-   2) Aspartic acid (D), Glutamic acid (E);-   3) Asparagine (N), Glutamine (Q);-   4) Arginine (R), Lysine (K);-   5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V);-   6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W);-   7) Serine (S), Threonine (T); and-   8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins    (1984)).

As used herein, a “variant” refers to a polypeptide, protein or analogthereof that comprises at least one amino acid substitution, deletion,insertion, or modification, provided that the variant retains thebiological activity of the native polypeptide. The term “variant,” insome aspects, is interchangeably used with the term “mutant.”

As used herein, an “allelic variant” refers to any of two or morepolymorphic forms of a gene occupying the same genetic locus. Allelicvariations arise naturally through mutation and, in some aspects, resultin phenotypic polymorphism within populations. In certain aspects, genemutations are silent (no change in the encoded polypeptide) or, in otheraspects, encode polypeptides having altered amino acid sequences.“Allelic variants” also refer to cDNAs derived from mRNA transcripts ofgenetic allelic variants, as well as the proteins encoded by them.

The term “derivative” refers to polypeptides that are covalentlymodified by conjugation to therapeutic or diagnostic agents, labeling(e.g., with radionuclides or various enzymes), covalent polymerattachment such as pegylation (derivatization with polyethylene glycol)and insertion or substitution by chemical synthesis of non-natural aminoacids. In some aspects, derivatives are modified to comprise additionalchemical moieties not normally a part of the molecule. In certainaspects, these derivatives are called chemically-modified derivatives.Such moieties, in various aspects, modulate the molecule's solubility,absorption, and/or biological half-life. The moieties, in various otheraspects, alternatively decrease the toxicity of the molecule andeliminate or attenuate any undesirable side effect of the molecule, etc.Moieties capable of mediating such effects are disclosed in Remington'sPharmaceutical Sciences (1980). Procedure for coupling such moieties toa molecule are well known in the art. For example, in some aspects, anADAMTS13 derivative is an ADAMTS13 molecule having a chemicalmodification which confers a longer half-life in vivo to the protein. Inone embodiment, the polypeptides are modified by addition of awater-soluble polymer known in the art. In a related embodiment,polypeptides are modified by glycosylation, PEGylation, and/orpolysialylation.

As used herein, a “fragment” of a polypeptide refers to any portion ofthe polypeptide smaller than the full-length polypeptide or proteinexpression product. Fragments are typically deletion analogs of thefull-length polypeptide, wherein one or more amino acid residues havebeen removed from the amino terminus and/or the carboxy terminus of thefull-length polypeptide. Accordingly, “fragments” are a subset ofdeletion analogs described below.

The term “recombinant” or “recombinant expression system” when used withreference, e.g., to a cell, indicates that the cell has been modified bythe introduction of a heterologous nucleic acid or protein or thealteration of a native nucleic acid or protein, or that the cell isderived from a cell so modified. Thus, for example, recombinant cellsexpress genes that are not found within the native (non-recombinant)form of the cell or express native genes that are otherwise abnormallyexpressed, underexpressed or not expressed at all. This term also meanshost cells which have stably integrated a recombinant genetic element orelements having a regulatory role in gene expression, for example,promoters or enhancers. Recombinant expression systems as defined hereinwill express polypeptides or proteins endogenous to the cell uponinduction of the regulatory elements linked to the endogenous DNAsegment or gene to be expressed. The cells can be prokaryotic oreukaryotic.

The term “recombinant,” when used herein to refer to a polypeptide orprotein, means that a polypeptide or protein is derived from recombinant(e.g., microbial or mammalian) expression systems. “Microbial” refers torecombinant polypeptides or proteins made in bacterial or fungal (e.g.,yeast) expression systems. The term “recombinant variant” refers to anypolypeptide differing from naturally occurring polypeptides by aminoacid insertions, deletions, and substitutions, created using recombinantDNA techniques. Guidance in determining which amino acid residues may bereplaced, added or deleted without abolishing activities of interest maybe found by comparing the sequence of the particular polypeptide withthat of homologous peptides and minimizing the number of amino acidsequence changes made in regions of high homology.

The term “agent” or “compound” describes any molecule, e.g., protein orpharmaceutical, with the capability of affecting a biological parameterin the disclosure.

A “control,” as used herein, can refer to an active, positive, negativeor vehicle control. As will be understood by those of skill in the art,controls are used to establish the relevance of experimental results,and provide a comparison for the condition being tested. In certainaspects, a control is a subject that does not receive an activeprophylactic or therapeutic composition. In certain aspects, a controlis a subject not experiencing SCD, VOC, ALI, and/or ARDS, for example,but not limited to a healthy control or a subject without any symptoms.

The term “reduces the severity,” when referring to a symptom of SCD, VOCin SCD, and/or ALI/ARDS, means that the symptom has delayed onset,reduced severity, reduced frequency, or causes less damage to thesubject. Generally, severity of a symptom is compared to a control,e.g., a subject that does not receive an active prophylactic ortherapeutic composition, or as compared to the severity of the symptomprior to administration of the therapeutic. In that case, a compositioncan be said to reduce the severity of a symptom of SCD, VOC in SCD,and/or ALI/ARDS if the symptom is reduced by about 10%, about 15%, about20%, about 25%, about 30%, about 35%, about 40%, about 50%, about 60%,about 70%, about 80%, about 90%, or about 100% (i.e., essentiallyeliminated), as compared to the control level of the symptom. In certainaspects, a composition can be said to reduce the severity of a symptomof SCD, VOC in SCD, and/or ALI/ARDS if the symptom is reduced betweenabout 10% to about 100%, about 20% to about 90%, about 30% to about 80%,about 40% to about 70% or about 50% to about 60%, as compared to thecontrol level of the symptom. In certain aspects, a composition can besaid to reduce the severity of a symptom of SCD, VOC in SCD, and/orALI/ARDS if the symptom is reduced between about 10% to about 30%, about20% to about 40%, about 30% to about 50%, about 40% to about 60%, about50% to about 70%, about 60% to about 80%, about 70% to about 90% orabout 80% to about 100%, as compared to the control level of thesymptom. In some aspects, treatment by methods of the disclosure reducesthe severity of the pain and/or other symptoms of VOC in SCD and/orALI/ARDS.

The terms “reduces the expression,” “reduces the level,” and “reducesthe activation” when referring to a biomarker of SCD, VOC in SCD, and/orALI/ARDS (for example, but not limited to VCAM-1, ICAM-1, P-NF-kB/NF-kBratio, ET-1, TXAS, HO-1, Hct, Hb, MCV, HDW, reticulocyte numbers, andneutrophil numbers), means that the expression, level, and/or activationof a biomarker has been reduced as compared to control. In that case, acomposition can be said to reduce the expression, level, and/oractivation of a biomarker of SCD, VOC in SCD, and/or ALI/ARDS if thebiomarker is reduced by about 10%, about 15%, about 20%, about 25%,about 30%, about 35%, about 40%, about 50%, about 60%, about 70%, about80%, about 90%, or about 100% (i.e., essentially eliminated), ascompared to the control. In certain aspects, a composition can be saidto reduce the expression, level, and/or activation of SCD, VOC in SCD,and/or ALI/ARDS if the expression, level, and/or activation is reducedbetween about 10% to about 100%, about 20% to about 90%, about 30% toabout 80%, about 40% to about 70% or about 50% to about 60%, as comparedto the control. In certain aspects, a composition can be said to reducethe expression, level, and/or activation of a biomarker of SCD, VOC inSCD, and/or ALI/ARDS if the biomarker is reduced between about 10% toabout 30%, about 20% to about 40%, about 30% to about 50%, about 40% toabout 60%, about 50% to about 70%, about 60% to about 80%, about 70% toabout 90% or about 80% to about 100%, as compared to the control.

The terms “increases the expression,” “increases the level,” and“increases the activation” when referring to a biomarker of SCD, VOC inSCD, and/or ALI/ARDS, means that the expression, level, and/oractivation of a biomarker has been increased as compared to control. Inthat case, a composition can be said to increase the expression, level,and/or activation of a biomarker of SCD, VOC in SCD, and/or ALI/ARDS ifthe biomarker is increased by about 10%, about 15%, about 20%, about25%, about 30%, about 35%, about 40%, about 50%, about 60%, about 70%,about 80%, about 90%, or about 100% (i.e., essentially eliminated), ascompared to the control. In certain aspects, a composition can be saidto increase the expression, level, and/or activation of SCD, VOC in SCD,and/or ALI/ARDS if the expression, level, and/or activation is increasedbetween about 10% to about 100%, about 20% to about 90%, about 30% toabout 80%, about 40% to about 70% or about 50% to about 60%, as comparedto the control. In certain aspects, a composition can be said toincrease the expression, level, and/or activation of a biomarker of SCD,VOC in SCD, and/or ALI/ARDS if the biomarker is increased between about10% to about 30%, about 20% to about 40%, about 30% to about 50%, about40% to about 60%, about 50% to about 70%, about 60% to about 80%, about70% to about 90% or about 80% to about 100%, as compared to the control.

The terms “effective amount” and “therapeutically effective amount” eachrefer to the amount of polypeptide, e.g., ADAMTS13 polypeptide, orcomposition used to support an observable level of one or morebiological activities of the ADAMTS13 polypeptide, as set forth herein.For example, an effective amount, in some aspects of the disclosure,would be the amount necessary to treat or prevent symptoms of VOC in SCDand/or ALI/ARDS.

A “subject” is given its conventional meaning of a non-plant,non-protist living being. In most aspects, the subject is an animal. Inparticular aspects, the animal is a mammal. In more particular aspects,the mammal is a human. In other aspects, the mammal is a pet orcompanion animal, a domesticated farm animal, or a zoo animal. Incertain aspects, the mammal is a mouse, rat, rabbit, guinea pig, pig, ornon-human primate. In other aspects the mammal is a cat, dog, horse, orcow. In various other aspects, the mammal is a deer, mouse, chipmunk,squirrel, opossum, or raccoon.

It also is specifically understood that any numerical value recitedherein includes all values from the lower value to the upper value,i.e., all possible combinations of numerical values between the lowestvalue and the highest value enumerated are to be considered to beexpressly stated in this application. For example, if a concentrationrange is stated as about 1% to 50%, it is intended that values such as2% to 40%, 10% to 30%, or 1% to 3%, etc., are expressly enumerated inthis specification. The values listed above are only examples of what isspecifically intended.

Ranges, in various aspects, are expressed herein as from “about” or“approximately” one particular value and/or to “about” or“approximately” another particular value. When values are expressed asapproximations, by use of the antecedent “about,” it will be understoodthat some amount of variation is included in the range. Such a range canbe within an order of magnitude, preferably within 50%, more preferablywithin 20%, still more preferably within 10%, and even more preferablywithin 5% of a given value or range. The allowable variation encompassedby the term “about” or “approximately” depends on the particular systemunder study, and can be readily appreciated by one of ordinary skill inthe art.

Sickle Cell Disease and Vaso-Occlusion in Sickle Cell Disease

In some aspects, the disclosure includes ADAMTS13 and compositionscomprising ADAMTS13 in the treatment, amelioration, and/or prevention ofVOC in SCD. SCD is a worldwide hereditary red blood cell disorder causedby a point mutation in the β-globin gene resulting in the synthesis ofpathological HbS, and abnormal HbS polymerization in hypoxic conditions.The two main clinical manifestations of SCD are chronic hemolytic anemiaand acute VOC, which are the principal causes of hospitalization of SCDpatients. Recent studies have underscored the central role of sicklevasculopathy in the generation of sickle cell-related acute events andchronic organ complications (Sparkenbaugh et al., Br. J. Haematol.162:3-14, 2013; De Franceschi et al., Semin. Thromb. Hemost. 226-36,2011; and Hebbel et al., Cardiovasc. Hematol. Disord. Drug Targets,9:271-92, 2009). The pathophysiology of these complications is based onintravascular sickling in capillaries and small vessels leading to VOC,impaired blood flow, vascular inflammation, and/or thrombosis withischemic cell damage.

The most common clinical manifestation of SCD is VOC. A VOC occurs whenthe microcirculation is obstructed by sickled red blood cells, causingischemic injury to the organ supplied and resultant pain. Pain crisesconstitute the most distinguishing clinical feature of SCD and are theleading cause of emergency department visits and/or hospitalizations foraffected SCD subjects or patients.

Approximately half the SCD subjects or patients with homozygous HbSdisease experience VOC. The frequency of crisis is extremely variable.Some SCD subjects or patients have as many as six or more episodesannually, whereas others may have episodes only at great intervals ornone at all. Each subjects or patient typically has a consistent patternfor crisis frequency.

The disclosure includes methods for reducing at least one symptom of VOCincluding, but not limited to, ischemia and pain (e.g., dactylitis,priapism, abdominal, chest, and joint), jaundice, bone infarction,abnormal breathing (e.g., tachypnea and shortness of breath), hypoxia,acidosis, hypotension, and/or tachycardia associated with VOC. Incertain aspects, VOC can be defined as a condition comprising one ormore of these symptoms. Pain crises begin suddenly. The crisis may lastseveral hours to several days and terminate as abruptly as it began. Thepain can affect any body part and often involves the abdomen,appendages, chest, back, bones, joints, and soft tissue, and it maypresent as dactylitis (bilateral painful and swollen hands and/or feetin children), acute joint necrosis or avascular necrosis, or acuteabdomen. With repeated episodes in the spleen, infarctions andautosplenectomy predisposing to life-threatening infection are usual.The liver also may infarct and progress to failure with time. Papillarynecrosis is a common renal manifestation of VOC, leading to isosthenuria(i.e., inability to concentrate urine).

Severe deep pain is present in the extremities, involving long bones.Abdominal pain can be severe, resembling acute abdomen; it may resultfrom referred pain from other sites or intra-abdominal solid organ orsoft tissue infarction. Reactive ileus leads to intestinal distentionand pain. The face also may be involved. Pain may be accompanied byfever, malaise, trouble breathing, painful erections, jaundice andleukocytosis. Bone pain is often due to bone marrow infarction. Certainpatterns are predictable, as pain tends to involve bones with the mostbone marrow activity and because marrow activity changes with age.During the first 18 months of life, the metatarsals and metacarpals canbe involved, presenting as dactylitis or hand-foot syndrome. Althoughthe above patterns describe commonly encountered presentations, any areaof the body of the subject with blood supply and sensory nerves can beaffected in VOC.

Often, no precipitating cause can be identified for what causes a VOC.However, because deoxygenated HbS becomes semi-solid, the most likelyphysiologic trigger of VOC is hypoxemia. This may be due to acute chestsyndrome or accompany respiratory complications. Dehydration also canprecipitate pain, since acidosis results in a shift of the oxygendissociation curve (Bohr effect), causing hemoglobin to desaturate morereadily. Hemoconcentration also is a common mechanism. Another commontrigger of VOC are changes in body temperature, whether an increase dueto fever or a decrease due to environmental temperature change. Loweredbody temperature likely leads to crises as the result of peripheralvasoconstriction.

In certain embodiments, VOC can be defined as having an increase inperipheral neutrophils as compared to a control. In certain embodiments,VOC can be defined as an increase in pulmonary vascular leakage (e.g.,increased number of leukocytes in a bronchoalveolar lavage (BAL) and/orprotein content (BAL protein (mg/mL)) as compared to a control.

In certain embodiments, increased levels of vascular activation (e.g.,as measured by increased expression, levels, and/or activity of VCAM-1and/or ICAM-1) in an organ, as compared to control, is a marker for VOC.In certain embodiments, increased levels of inflammatory vasculopathy(e.g., as measured by increased expression, levels, and/or activity ofVCAM-1 and/or ICAM-1) in an organ, as compared to control, is a markerfor VOC. In certain embodiments, increased levels of vascular activationand inflammatory vasculopathy in a tissue, as compared to control, is amarker for VOC. In certain embodiments, the organ is lung and/or kidney.In certain embodiments, the organ is kidney.

In certain embodiments, VOC can be defined as the increased expression,levels, and/or activation of at least one of NF-kB (wherein activationof NF-kB is measured by P-NF-kB or the ratio of P-NF-kB/NF-kB), VCAM-1and ICAM-1 as compared to control. In certain embodiments, VOC can bedefined as increased expression or level of at least one of endothelin-1(ET-1), thromboxane synthase (TXAS), and heme-oxygenase-1 (HO-1) ascompared to control. In certain embodiments, these increases are seen inlung tissue. In certain embodiments, these increases are seen in kidneytissue. In certain embodiments, increased expression and/or levels ofTXAS, ET-1, and VCAM-1, and activation of NF-kB in the kidney tissue aremarkers for VOC.

In certain embodiments, VOC can be defined by hematology parameters. Incertain embodiments, VOC can be defined as a decrease in the levels ofat least one of Hct, Hb, MCV, and MCH as compared to control. In certainembodiments, VOC can be defined as a decrease in the levels of at leasttwo of Hct, Hb, MCV, and MCH as compared to control. In certainembodiments, VOC can be defined as a decrease in the levels of at leastthree of Hct, Hb, MCV, and MCH as compared to control. In certainembodiments, VOC can be defined as an increase in the levels of at leastone of CHCM, HDW, neutrophil numbers, and LDH as compared to control. Incertain embodiments, VOC can be defined as an increase in the levels ofat least two of CHCM, HDW, neutrophil numbers, and LDH as compared tocontrol. In certain embodiments, VOC can be defined as an increase inthe levels of at least three of CHCM, HDW, neutrophil numbers, and LDHas compared to control. In certain embodiments, VOC can be defined as adecrease in Hct levels as compared to control. In certain embodiments,VOC can be defined as a decrease in Hb levels as compared to control. Incertain embodiments, VOC can be defined as a decrease in MCV as comparedto control. In certain embodiments, VOC can be defined as a decrease inMCH as compared to control. In certain embodiments, VOC can be definedas an increase in CHCM as compared to control. In certain embodiments,VOC can be defined as an increase in HDW as compared to control. Incertain embodiments, VOC can be defined as an increase in neutrophilnumbers as compared to control. In certain embodiments, VOC can bedefined as an increase in LDH as compared to control. In certainembodiments, VOC can be defined as a decrease in the levels of at leastone of Hct, Hb, MCV, and MCH as compared to control and/or an increasein the levels of at least one of CHCM, HDW, neutrophil numbers, and LDHas compared to control. In certain embodiments, VOC can be defined as adecrease in the levels of Hct, Hb, MCV, and MCH as compared to controland/or an increase in the levels of CHCM, HDW, neutrophil numbers, andLDH as compared to control.

Models of SCD and Methods of Testing Effectiveness of Prophylaxis orTreatment

In some embodiments, the disclosure includes study of the effects of arecombinant ADAMTS13 (i.e., BAX930/SHP655) in a mouse model of SCD (TimTownes mouse) during acute SCD related events, mimicked by exposing SCDmice to hypoxia. Studies are carried out under normoxic and hypoxicconditions, wherein efficacy of the prophylaxis or treatment dose(s) inthe mouse model (including measuring overall survival) and biologicaleffects of the treatment(s) with BAX930/SHP655 on lung injury andvascular inflammation are studied after exposing sickle cell diseasemice to hypoxia.

In some embodiments, a transgenic mouse model of SCD is used (Kalish etal., Haematologica 100:870-80, 2015). In some aspects, healthy control(Hba^(tm1(HBA)Tow) Hbb^(tm3(HBG1,HBB)Tow)) and SCD (Hba^(tm1(HBA)Tow)Hbb^(tm2(HBG1,HBB)*^()Tow)) mice are exposed to hypoxia/re-oxygenation(H/R) stress (Kalish et al., infra). Such H/R stress has been shown tobiologically recapitulate the acute VOC and organ damage observed inacute VOC in human SCD patients. In some aspects, healthy (AA) and SCD(SS) mice are subjected to hypoxia (e.g., about 7 or 8% oxygen) forcertain time periods (e.g., about 10 hours) followed by certain timeperiods (e.g., 3 hours) of re-oxygenation (e.g., about 21% oxygen, roomair condition) (Kalish et al., infra).

In various aspects, models of SCD and controls are subject to conditionsof normoxia or hypoxia. In normoxia experiments, healthy control (AA)and SCD (SS) mice receive a single intravenous administration of eitherrADAMTS13 (e.g., 2,940 FRETS-U/kg (˜3,200 IU/kg)) or buffer (vehicle) ata fixed volume (e.g., 10 mL/kg) and are subject to normoxic (e.g., about21% oxygen, room air condition) conditions. Animals are studied forvaried periods of time after treatment with ADAMTS13 or vehicle andexposure to normoxia or hypoxia. Blood is collected and complete bloodcount (CBC) is measured. A CBC is a blood test used to evaluate overallhealth and detect a wide range of disorders, including among otherthings, anemia. Various other endpoints, including but not limited to,hematology, coagulation parameters, biomarkers of inflammation,vasculopathy, and histopathology are measured.

In exemplary aspects, hypoxia experiments are carried out, whereinhealthy control (AA) and SCD (SS) mice receive a single intravenousadministration of ADAMTS13 (e.g., 500 IU/kg, 1,000 IU/kg or 3,200 IU/kg)or vehicle at an affixed volume (e.g., 10 mL/kg). In certainembodiments, the dose administered to a human subject is about 10% thatadministered to a rodent (e.g., mouse) subject. In certain embodiments,the dose administered to a human subject is about 9% that administeredto a rodent (e.g., mouse) subject. In certain embodiments, the doseadministered to a human subject is about 8% that administered to arodent (e.g., mouse) subject. In certain embodiments, the doseadministered to a human subject is about 7% that administered to arodent (e.g., mouse) subject. In certain embodiments, the doseadministered to a human subject is less than about 10%, e.g., about 7%to about 10%, that administered to a rodent (e.g., mouse) subject.

After injection (e.g., about 1-3 hours after injection), mice areexposed to hypoxia (e.g., about 7% or 8% oxygen) for a time period(e.g., about 10 hours) followed by a time period of re-oxygenation(e.g., about 3 hours) to mimic SCD related VOC events. In some aspects,the same parameters as detailed for normoxic studies are evaluated.

In additional exemplary aspects, hypoxia experiments are carried out,wherein healthy control (AA) and SCD (SS) mice are exposed to hypoxia(e.g., about 8% oxygen, or higher) for a time period (e.g., about 10hours) followed by a time period of re-oxygenation (e.g., about 3 hours)to mimic SCD related VOC events. Then, at various time points thereafterincluding, but not limited to, immediately after, or about 1, 3, 6, 12,24, 36, 48 or 72 hours after the experimentally-induced vaso-inclusiveevent, mice receive either a single intravenous administration ofADAMTS13 (e.g., 500 IU/kg, 1,000 IU/kg or 3,200 IU/kg) or vehicle at anaffixed volume (e.g., 10 mL/kg), or multiple injections at 12 or 24intervals. In some aspects, the same parameters as detailed for normoxicstudies are evaluated.

In various aspects, any target tissue is examined for effectiveness oftreatment with ADAMTS13 in in vitro or in vivo models and/or underconditions of VOC. In some aspects, organ tissue includes, but is notlimited to, lung, liver, pancreas, skin, retina, prostate, ovary, lymphnode, adrenal gland, kidney, heart, gallbladder or GI tract. In someaspects, organ tissue includes, but is not limited to the lungs, liver,spleen, and/or kidneys.

For example, in some aspects, target tissues are collected to examineeffects of ADAMTS13 under conditions of normoxia or hypoxia. Tissues arefrozen and/or fixed in formalin. Frozen tissues are used for immunoblotanalysis with specific antibodies against nuclear factor-kappa B(NF-kB), endothelin-1 (ET-1), heme-oxygenase 1 (HO-1), intercellularadhesion molecule-1 (ICAM-1), thromboxane synthase (TXAS), and vascularcell adhesion molecule-1 (VCAM-1). Fixed organs are used for standardpathology (H&E staining).

In some embodiments, markers of vaso-constriction, platelet aggregation,inflammation, oxidative stress, anti-oxidant response and/or tissuedamage are measured to determine effectiveness of treatment. In someaspects, nuclear factor kappa B is measured in both its normal (NF-kB)and activated (P-NF-kB) forms. NF-kB is a transcriptional factor whichhas been described to coordinate the inflammatory and anti-oxidantresponse. The ratio between the activated and the normal forms isevaluated. In some aspects, ET-1 is measured. ET-1 is a potentvasoconstrictor that is produced by vascular endothelial cells. ET-1plays a role in several pathophysiological processes, includingcardiovascular hypertrophy, pulmonary hypertension and chronic renalfailure. In some aspects, HO-1 is measured. HO-1 is the inducible,rate-limiting enzyme in the catabolism of heme and might attenuate theseverity of outcomes from vaso-occlusive and hemolytic crises, acting asa vaso-protective anti-oxidant. In some aspects, ICAM-1 is measured.ICAM-1 is continuously present in low concentrations in the membranes ofleukocytes and endothelial cells. Although ICAM-1 does not appear to beinvolved in sickle cell adhesion to vascular endothelium, ICAM-1 mayexacerbate VOC by promoting leukocyte adhesion. In some aspects, TXAS ismeasured. TXAS is an endoplasmic reticulum membrane protein thatcatalyzes the conversion of prostaglandin H2 to thromboxane A2. TXAS isa potent vasoconstrictor and inducer of platelet aggregation. Thus, TXASis a potent inducer of vaso-constriction and platelet aggregation. TXASplays a role in several pathophysiological processes includinghemostasis, cardiovascular disease, and stroke. In some aspects, VCAM-1is measured. VCAM-1 mediates the adhesion of lymphocytes and other bloodcells to the vascular endothelium and therefore may contribute tovaso-occlusive events. In some aspects, inflammatory cell infiltratesare measured in organ tissue.

In exemplary aspects, immunoblot analyses with specific antibodiesagainst NF-kB, ET-1, HO-1, ICAM-1, TXAS, and VCAM-1 are carried out tomeasure the expression of these enzymes in the cells and tissues ofmodels or subjects of the disclosure to determine effectiveness oftreatment. In exemplary aspects, the expression of NF-kB, ET-1, HO-1,ICAM-1, TXAS, and/or VCAM-1 is measured in organ tissue from AA and SCDmice treated with either vehicle or ADAMTS13. In certain embodiments,organs include, but are not limited to, lung, liver, pancreas, skin,retina, prostate, ovary, lymph node, adrenal gland, kidney, heart,gallbladder or GI track. In certain embodiments, the organ is lung,liver, spleen, and/or kidney.

In certain embodiments, administration of ADAMTS13 results in reducedlevels of vascular activation and/or inflammatory vasculopathy in anorgan as compared to control. In certain embodiments, the organ is lung.In certain embodiments, the organ is kidney.

In certain embodiments, administration of ADAMTS13 results in reducedexpression, level, and/or activation of at least one of VCAM-1, ICAM-1,NF-kB (wherein reduced activation of NF-kB is measured by P-NF-kB or theratio of P-NF-kB/NF-kB), ET-1, TXAS, and HO-1 as compared to control. Incertain embodiments, administration of ADAMTS13 results in reducedexpression, level, and/or activation of at least two of VCAM-1, ICAM-1,NF-kB, ET-1, TXAS, and HO-1 as compared to control. In certainembodiments, administration of ADAMTS13 results in reduced expression,level, and/or activation of at least three of VCAM-1, ICAM-1, NF-kB,ET-1, TXAS, and HO-1 as compared to control. In certain embodiments,administration of ADAMTS13 results in reduced expression, level, and/oractivation of at least four of VCAM-1, ICAM-1, NF-kB, ET-1, TXAS, andHO-1 as compared to control. In certain embodiments, administration ofADAMTS13 results in reduced expression, level, and/or activation of atleast five of VCAM-1, ICAM-1, NF-kB, ET-1, TXAS, and HO-1 as compared tocontrol. In certain embodiments, administration of ADAMTS13 results inreduced expression, level, and/or activation of VCAM-1, ICAM-1, NF-kB,ET-1, TXAS, and HO-1 as compared to control. In certain embodiments,administration of ADAMTS13 results in reduced expression, level, and/oractivation of VCAM-1 as compared to control. In certain embodiments,administration of ADAMTS13 results in reduced expression, level, and/oractivation of ICAM-1 as compared to control. In certain embodiments,administration of ADAMTS13 results in reduced expression, level, and/oractivation of VCAM-1 and ICAM-1 as compared to control. In certainembodiments, administration of ADAMTS13 results in reduced expressionand/or level of ET-1 as compared to control. In certain embodiments,administration of ADAMTS13 results in reduced expression and/or level ofTXAS as compared to control. In certain embodiments, administration ofADAMTS13 results in reduced expression and/or level of HO-1 as comparedto control. In certain embodiments, administration of ADAMTS13 resultsin reduced ratio of P-NF-kB/NF-kB as compared to control. In certainembodiments, administration of ADAMTS13 results in a reduction of atleast one of P-NF-kB/NF-kB ratio, ET-1 expression and/or level, TXASexpression and/or level, and HO-1 expression and/or level as compared tocontrol. In certain embodiments, administration of ADAMTS13 results in areduction of P-NF-kB/NF-kB ratio, ET-1 expression and/or level, TXASexpression and/or level, and HO-1 expression and/or level as compared tocontrol. In certain embodiments, the organ is lung. In certainembodiments, the organ is kidney.

In further exemplary aspects, the measurement of these markers iscarried out after the animal models are subject to conditions of hypoxiaand reoxygenation (H/R) as described herein. In further exemplaryaspects, the measurement of these markers is carried out after thesubjects experience VOC.

In some embodiments, blood flow is measured as an indicatory oftreatment effectiveness. In some embodiments, blood flow is measured by,but not limited to, ultrasound, PET, fMRI, NMR, laser Doppler,electromagnetic blood flow meter, or a wearable device.

In some embodiments, reduction or prevention of thrombosis is ameasurement of the effectiveness of the treatment. In some embodiments,the presence of thrombosis is measured by, but not limited to,histopathological examination, ultrasound, D-dimer test, venography,MRI, or CT/CAT scan. In some aspects, thrombus formation is determinedin organ tissue.

In some embodiments, reduction or prevention of pulmonary vascularleakage (i.e., lung leakage and damage) is a measurement of theeffectiveness of the treatment. In some embodiments, bronchoalveolarlavage (BAL) measurements or parameters (total protein and leukocytecontent) are measured as markers of pulmonary vascular leakage (todetermine the extent of lung damage and effectiveness of treatment(e.g., treatment with ADAMTS13)). Pulmonary leakage can result in anincrease in protein and/or leukocyte content in the BAL. BAL fluids arecollected and cellular contents are recovered by centrifugation andcounted by microcytometry as previously reported (Kalish et al.,Haematologica 100:870-80, 2015, incorporated herein by reference in itsentirety and for all purposes). In some embodiments, reduction orprevention of an increase in peripheral neutrophils is a measurement ofthe effectiveness of the treatment. The percentage of neutrophils isdetermined on cytospin centrifugation and the supernatant fluids areused for determination of total protein content (Kalish et al., supra).

In some embodiments, improvement of lung function is measured as anindicatory of treatment effectiveness. Lung function can be measured by,but not limited to, a peak flow test, a spirometry and reversibilitytest, a lung volume test, a gas transfer test, a respiratory muscletest, exhaled carbon monoside test, or a exhaled nitric oxide test.

In some embodiments, hematology parameters are measured to determineeffectiveness of treatment (e.g., treatment with ADAMTS13). Thefollowing hematology parameters are determined: lactate dehydrogenase(LDH) as a general marker of cell damage; hematocrit (Hct) and meancorpuscular volume (MCV), as a measure of erythrocyte viability;hemoglobin (Hb), mean corpuscular hemoglobin (MCH) and cell hemoglobinconcentration (CHCM), as indicators of oxygen binding capacity;heterogeneity of red cell distribution (HDW), as an indicator of thepresence of dense red cells; reticulocyte count, as an indicator ofanemia status; and neutrophil count, as an indicator of systemicinflammatory status.

In certain embodiments, administration of ADAMTS13 ameliorates thereduction of the levels of at least one of Hct, Hb, MCV and MCH in theblood as compared to control. In certain embodiments, administration ofADAMTS13 ameliorates the reduction of the levels of at least two of Hct,Hb, MCV and MCH in the blood as compared to control. In certainembodiments, administration of ADAMTS13 ameliorates the reduction of thelevels of at least three of Hct, Hb, MCV and MCH in the blood ascompared to control. In certain embodiments, administration of ADAMTS13ameliorates the reduction of the levels of Hct, Hb, MCV and MCH in theblood as compared to control. In certain embodiments, administration ofADAMTS13 ameliorates the increase of at least one of CHCM, HDW, LDH, andneutrophil number as compared to control. In certain embodiments,administration of ADAMTS13 ameliorates the increase of at least two ofCHCM, HDW, LDH, and neutrophil number as compared to control. In certainembodiments, administration of ADAMTS13 ameliorates the increase of atleast three of CHCM, HDW, LDH, and neutrophil number as compared tocontrol. In certain embodiments, administration of ADAMTS13 amelioratesthe increase of CHCM, HDW, LDH, and neutrophil number as compared tocontrol. In certain embodiments, ADAMTS13 ameliorates the reduction ofHct, Hb, MCV, and MCH levels and ameliorates the increase in CHCM, HDW,LDH, and neutrophil levels as compared to control.

In certain embodiments, administration of ADAMTS13 results in anincrease in the levels of at least one of Hct, Hb, MCV and MCH in theblood as compared to control. In certain embodiments, administration ofADAMTS13 results in an increase in the levels of at least two of Hct,Hb, MCV and MCH in the blood as compared to control. In certainembodiments, administration of ADAMTS13 results in an increase in thelevels of at least three of Hct, Hb, MCV and MCH in the blood ascompared to control. In certain embodiments, administration of ADAMTS13results in an increase in the levels of Hct, Hb, MCV and MCH in theblood as compared to control. In certain embodiments, administration ofADAMTS13 results in a decrease in at least one of CHCM, HDW, LDH, andneutrophil number as compared to control. In certain embodiments,administration of ADAMTS13 results in a decrease in at least two ofCHCM, HDW, LDH, and neutrophil number as compared to control. In certainembodiments, administration of ADAMTS13 results in a decrease in atleast three of CHCM, HDW, LDH, and neutrophil number as compared tocontrol. In certain embodiments, administration of ADAMTS13 results in adecrease in CHCM, HDW, LDH, and neutrophil number as compared tocontrol. In certain embodiments, ADAMTS13 results in an increase of Hct,Hb, MCV, and MCH levels and a reduction in CHCM, HDW, LDH, andneutrophil levels as compared to control.

In some embodiments, methods of measuring the levels of VWF and ofultra-large VWF multimers are used. In SCD patients, increased levels ofVWF and of ultra-large VWF multimers have been observed and areassociated with acute vaso-occlusive events. The increased levels ofcirculating VWF multimers are dependent on the activity of ADAMTS13 thatcleaves the hyperadhesive ultra-large VWF under conditions of high fluidshear stress, playing an important role in maintaining a proper balanceof hemostatic activity and thrombotic risk. More specifically, ADAMTS13cleaves VWF between amino acid residues Tyr¹⁶⁰⁵ and Met¹⁶⁰⁶, whichcorresponds to amino acid residues 842-843 after cleavage of thepreprosequence. It is this ADAMTS13-mediated cleavage that is largelyresponsible for VWF multimer size, which correlates with primaryhemostatic activity. Methods of measuring VWF and ultra-large VWFmultimers, including various types of immunoblot analyses with specificantibodies against VWF, are carried out to measure the expression orlevel of VWF. Additionally, other known methods of measuring VWF areincluded in various aspects of the disclosure.

In some aspects, effectiveness is measured by decreased organ damage ascompared to control or baseline measurements. In some embodiments, organdamage is measured by radiological imaging such as, but not limited to,CT/CAT scanning, ultrasound, X-ray, MRI, and nuclear medicine. In someembodiments, organ damage is measured by a change in various biomarkersincluding, but not limited to, blood urea nitrogen (BUN), creatinine,BUN/creatinine ratio, troponin, neuron-specific enolase (NSE). In someembodiments, tissue changes are measured by histopathologicalexamination.

One of ordinary skill in the art is able to select an appropriatemeasure of any biomarker disclosed herein associated with the organ(defined above) and/or bodily fluid to be measured. Bodily fluidsinclude, but are not limited to, blood (including blood plasma and bloodserum), lymph, cerebrospinal fluid, lactation products (e.g., milk),amniotic fluids, urine, saliva, perspiration, tears, menses, feces, andincluding fractions thereof.

In some aspects, effectiveness is measured by assessing theQuality-of-Life of the subject (e.g., using the Adult Sickle CellQuality-of-Life Measurement Information System (ASCQ-Me) as reported byTreadwell et al., Clin. J. Pain 30(10):902-915 (2016)). The ASCQ-Mecenters around seven topics: emotional impact (five question surveyrelated to emotional distress (e.g., hopelessness, loneliness,depression, and worry); pain episode frequency and severity (number ofepisodes, time since last episode; severity of pain in last attack on ascale from 1-10); how long did the attack last, how much did the attackimpact your life); pain impact (asking about the frequency and severityand how it impacted activities); sickle cell disease medical historychecklist; sleep impact (how easy to fall asleep, how often cannot fallasleep); social functioning impact (reliance on others, how healthimpacted activities); and stiffness impact (stiff joints causingsleeplessness, movement during the day, movement upon wakefulness).

In various aspects, effectiveness of prophylaxis and/or treatment isdetermined by measuring pain severity (e.g., as measured by a painrating scale), pain relief, perceived need for medication, treatmentsatisfaction, the frequency of VOC occurrence, the duration of VOCepisode, the length and/or duration of hospitalization, costs associatedwith a hospital stay, and/or the duration of the requirement for painmedication (e.g., i.v. opiates).

In certain aspects, pain severity is measured using the McGill/MelzackPain Questionnaire (Melzack et al., Pain 1975 September; 1(3):277-99),in which the subject selects one or more words that best describe theirpain. In certain aspects, pain severity is measured using the VisualAnalog Scale (VAS). The VAS is a 10 cm, non-hatched line anchored withone end as “no pain” and the other end as “worst pain possible.”Patients are instructed to mark on the line their level of pain betweenthe two anchors. VAS scores are calculated by measuring the distance, incentimeters, between the “no pain” anchor and the patient's markindicating their level of pain resulting in a pain severity scoreranging from 0 mm to 10 cm. In certain aspects, pain severity ismeasured using the Numeric Rating Scale (NRS). NRS is an 11-point scaleanchored with “no pain” and “worst pain possible.” Patients areinstructed to report their current level of pain on a scale from 0 to 10where 0 means no pain and 10 means the worst pain possible.

In certain aspects, pain relief can be measured as a global assessmentof how a patient's pain may have changed since the last assessment(i.e., current assessment minus previous assessment) as used to anchorthe changes noted on the NRS and VAS scales. Patients reported painrelief in response to the question: “Compared to the last time youmarked your pain, tell us how much your pain has changed.” Patientscould respond that their pain was “a lot worse,” “a little worse,” “thesame,” “a little better,” or “a lot better.”

In certain aspects, the need for medication can be patient or healthcareworker reported.

In certain aspects, treatment satisfaction can be a patient-reported.Reporting can be on a scale from “not at all,” “somewhat satisfied(happy),” “very satisfied (happy),” or “do not know.”

Acute Lung Injury and Acute Respiratory Distress Syndrome

In some embodiments, the disclosure includes ADAMTS13, compositionscomprising ADAMTS13, and methods of using ADAMTS13 in the treatment,amelioration, and/or prevention of acute lung injury (ALI) and acuterespiratory distress syndrome (ARDS), including the resultantventilator-associated lung injury. Pathogenesis of ALI/ARDS is explainedby injury to both the vascular endothelium and alveolar epithelium.Phase III clinical trials by the NHLBI ARDS Network have resulted inimprovement in survival and a reduction in the duration of mechanicalventilation with a lung-protective ventilation strategy and fluidconservative protocol. However, there is a strong unmet medical need foradditional treatments because there are no existing specificpharmacologic therapies for ALI/ARDS. Therefore, the use of ADAMTS13 inthe treatment of ALI/ARDS represents a breakthrough in the treatment ofALI/ARDS.

ALI, in some aspects, is a disorder of acute inflammation that causesdisruption of the lung endothelial and epithelial barriers. Cellularcharacteristics of ALI include loss of alveolar-capillary membraneintegrity, excessive transepithelial neutrophil migration, and releaseof pro-inflammatory, cytotoxic mediators. Several studies havedocumented increased release of VWF and upregulation of intracellularadhesion molecule-1 (ICAM-1) following endothelial injury (Johnson,supra). Transepithelial neutrophil migration is an important feature ofALI because neutrophils are the primary perpetrators of inflammation.Prolonged activation of neutrophils contributes to basement membranedestruction and increased permeability of the alveolar-capillarybarrier. (Johnson, supra).

ARDS, in some aspects, includes acute onset tachypnea, hypoxemia,diffuse pulmonary infiltrates, and loss of lung compliance characterizedby high short-term mortality in adults (Walkey, supra). Therapeuticstrategies for ARDS focus upon treating the underlying etiology andproviding supportive care that reduces the progression of lung injury.Most patients with ARDS develop respiratory failure severe enough torequire mechanical ventilatory support. Mechanical ventilation can causefurther injury to the lungs called ventilator-associated lung injury(VALI) from the combined mechanistic forces of overdistension and cyclicrecruitment. VALI produces “biotrauma” from systemic release ofinflammatory cytokines. Currently, the primary goal for management ofARDS is the reduction of VALI. (Walkey, supra).

ADAMTS13 significantly reduced the markers of lung injury and vasculardysfunction in normal mice. More specifically, the disclosure shows thatdosing of normal (control) mice with recombinant ADAMTS13 under hypoxicconditions resulted in reduced lung expression of various proteinmarkers of lung injury and vascular dysfunction, which indicates thatADAMTS13 can be used in treating or ameliorating lung damage resultingfrom acute lung injury characterized by the sudden onset of pulmonaryedema (including inflammatory pulmonary edema) secondary to myriad localor systemic insults, including bilateral, inflammatory pulmonaryinfiltrates and impaired oxygenation or hypoxemia.

In certain embodiments, ALI and/or ARDS can be defined by one of more,but not limited to, ischemia, abnormal breathing (e.g., tachypnea andshortness of breath), non-cardiogenic pulmonary edema, pulmonaryinfiltrates, decreased oxygenation, and decreased ventilation associatedwith ALI/ARDS. The disclosure includes methods for reducing symptoms ofALI/ARDS including, but not limited to, at least one of ischemia,abnormal breathing (e.g., tachypnea and shortness of breath),non-cardiogenic pulmonary edema, pulmonary infiltrates, decreasedoxygenation, decreased ventilation, and combinations thereof associatedwith ALI/ARDS.

In certain embodiments, ALI and/or ARDS can be defined as having anincrease in peripheral neutrophils as compared to a control. In certainembodiments, ALI and/or ARDS can be defined as an increase in pulmonaryvascular leakage (e.g., increased number of leukocytes in abronchoalveolar lavage (BAL) and/or protein content (BAL protein(mg/mL)) as compared to a control.

In certain embodiments, increased levels of vascular activation in anorgan, as compared to control, is a marker for ALI and/or ARDS. Incertain embodiments, increased levels of inflammatory vasculopathy in anorgan, as compared to control, is a marker for ALI and/or ARDS. Incertain embodiments, increased levels of vascular activation andinflammatory vasculopathy in a tissue, as compared to control, is amarker for ALI and/or ARDS. In certain embodiments, the organ is lungand/or kidney.

In certain embodiments, ALI and/or ARDS can be defined as the increasedexpression, levels, and/or activation of at least one of NF-kB (whereinactivation of NF-kB is measured by P-NF-kB or the ratio ofP-NF-kB/NF-kB), VCAM-1, and/or ICAM-1 as compared to control. In certainembodiments, ALI and/or ARDS can be defined as increased expression orlevel of at least one of endothelin-1 (ET-1), thromboxane synthase(TXAS), and heme-oxygenase-1 (HO-1) as compared to control. In certainembodiments, these increases are seen in lung tissue. In certainembodiments, these increases are seen in kidney tissue. In certainembodiments, increased expression and/or levels of TXAS and ET-1 andactivation of NF-kB in the kidney tissue are markers for ALI and/orARDS.

In certain embodiments, ALI and/or ARDS can be defined by hematologyparameters. In certain embodiments, ALI and/or ARDS can be defined as anincrease in neutrophil numbers as compared to control. In certainembodiments, ALI and/or ARDS can be defined as an increase in neutrophilnumbers as compared to control.

In certain embodiments, ALI and/or ARDS can also be defined by anincrease of at least one of the following serum biomarkers:surfactant-associated protein (SP)-A, SP-B, SP-D, KL-6/MUC1, IL-1, IL-2,IL-3, IL-6, IL-8, IL-10, IL-15, TNFα, adhesion molecules (e.g., E,L-selectin), MMP-9, LTB4, and Ferritin. See e.g., Tzouvelekis et al.,Respiratory Research 2005, 6:62), which his incorporated herein in itsentirety.

Models of ALI/ARDS and Methods of Testing Effectiveness of Prophylaxisor Treatment

Animal models for ALI are described in Matute-Bello et al., Am. J.Physiol. Lung Cell Mol. Physiol. 295(3):L379-99, 2008, which isincorporated by reference in their entireties for all purposes. In someinstances, ALI in humans is characterized histopathologically byneutrophilic alveolitis, injury of the alveolar epithelium andendothelium, hyaline membrane formation, and microvascular thrombi. Insome aspects, animal models of experimental lung injury can been used toinvestigate mechanisms of ALI. For example, you can reproduce riskfactors for ARDS, such as sepsis, lipid embolism secondary to bonefracture, acid aspiration, ischemia-reperfusion of pulmonary or distalvascular beds, and other clinical risks. In certain aspects, animalmodels of ALI reproduce the mechanisms and consequences of ALI,including the physiological and pathological changes that occur. Inhumans, the intrapulmonary inflammatory response begins before the onsetof clinically defined ALI and is most intense about 3 days after theonset of ALI and/or ARDS. The acute inflammatory phase is followed by achronic fibroproliferative phase. For example, pulmonary function testscan show restriction, consistent with the parenchymal fibrosis seen inlung biopsies or autopsy specimens.

Animal models for ARDS are described in Bastarche et al., Dis. Model.Mech. 2(5-8):218-23, 2009, which is incorporated by reference in theirentireties for all purposes. For example, in humans, pneumonia andsepsis are the two most common predisposing conditions for thedevelopment of ARDS. In some aspects, these conditions can be modeled inmice by using the Gram-negative bacterial endotoxin LPS, which can beadministered either directly to the lungs through intratrachealinjection or inhalation, or given intraperitoneally or intravenously toincite a systemic inflammatory response. Mice treated with intratrachealLPS have an acute and robust inflammatory cell influx to the lung withresolution by 48 hours. Intraperitoneal LPS activates systemicinflammation and is associated with a mild lung injury. This injury canbe augmented with either repeated injections of LPS or the implantationof an LPS pump in the peritoneal cavity to continually release LPS forhours, or even days. Another commonly used model of lung injury ishyperoxia, where mice breathe a high partial pressure of oxygen that ishighly toxic to the alveolar epithelium and causes extensive alveolarepithelial injury with only a modest amount of inflammation. Anadditional commonly studied model is ventilator-induced lung injury,which correlates excellently to human ventilator-induced lung injury;however, in the absence of an additional stimulus or extremely hightidal volumes, this model does not induce substantial lung injury inmice. One recent study showed a modest degree of lung inflammation,vascular leak and activation of alveolar coagulation with tidal volumesof 15 ml/kg compared with low tidal volumes of 7.5 ml/kg. To get a moresevere injury, higher tidal volumes (as high as 35 ml/kg) are required.A recent, comprehensive review on animal models of ALI by Matute-Belloet al. (Am. J. Physiol. Lung Cell Mol. Physiol. 295:L379-L399, 2008),also incorporated herein by reference for all purposes discusses eachmodel in great detail.

In certain aspects, the disclosed methods and composition can improvesymptoms such as, but not limited to, ischemia, abnormal breathing(e.g., tachypnea and shortness of breath), non-cardiogenic pulmonaryedema, pulmonary infiltrates (e.g., measured by chest radiography),decreased oxygenation (e.g., measured by pulse oximetry [SpO₂] orarterial blood gas [PaO₂]), and decreased ventilation (e.g., measured byend-tidal CO₂ or arterial blood gas [PaCO₂], a decrease in the days on aventilator or an increase in ventilator free days) associated withALI/ARDS.

In various aspects, effectiveness of prophylaxis and/or treatment isdetermined by measuring survival, length and/or frequency ofhospitalization, length and/or duration of ICU admissions, and/or costsassociated with a hospital stay.

In various aspects, effectiveness of prophylaxis and/or treatment isdetermined by measuring a decrease in the number of and/or severity ofALI and/or ARDS associated complications. Complications can include, butare not limited to, pulmonary complications (e.g., barotrauma,volutrauma, pulmonary embolism, pulmonary fibrosis,ventilator-associated pneumonia (CAP), and airway complications);gastrointestinal complications (e.g., bleeding (ulcer, lesions),dysmotility, pneumoperitoneum, and bacterial translocation); cardiaccomplications (e.g., abnormal heart rhythms, and myocardialdysfunction); kidney (acute kidney failure and positive fluid balance);mechanical complications (e.g., vascular injury, pneumothorax (byplacing pulmonary artery catheter), tracheal injury/stenosis (result ofintubation and/or irritation by endotracheal tube); nutritionalcomplications (e.g., malnutrition (catabolic state), electrolytedeficiency); and general complications (e.g., muscle weakness andexercise tolerance).

In certain embodiments, measurement of the effectiveness of treatment,amelioration, and prevention is the same as those disclosed above forVOC.

In certain embodiments, organs include, but are not limited to, lung,liver, pancreas, skin, retina, prostate, ovary, lymph node, adrenalgland, kidney, heart, gallbladder or GI track. In certain embodiments,the organ is lungs, liver, spleen, and/or kidneys.

In certain embodiments, administration of ADAMTS13 results in reducedlevels of vascular activation and/or inflammatory vasculopathy in anorgan as compared to control. In certain embodiments, the organ is lung.In certain embodiments, the organ is kidney.

In certain embodiments, administration of ADAMTS13 results in reducedexpression, level, and/or activation of at least one of ICAM-1, NF-kB(wherein reduced activation of NF-kB is measured by P-NF-kB or the ratioof P-NF-kB/NF-kB), ET-1, TXAS, and HO-1 as compared to control. Incertain embodiments, administration of ADAMTS13 results in reducedexpression, level, and/or activation of at least two of ICAM-1, NF-kB,ET-1, TXAS, and HO-1 as compared to control. In certain embodiments,administration of ADAMTS13 results in reduced expression, level, and/oractivation of at least three of ICAM-1, NF-kB, ET-1, TXAS, and HO-1 ascompared to control. In certain embodiments, administration of ADAMTS13results in reduced expression, level, and/or activation of at least fourof ICAM-1, NF-kB, ET-1, TXAS, and HO-1 as compared to control. Incertain embodiments, administration of ADAMTS13 results in reducedexpression, level, and/or activation of ICAM-1, NF-kB, ET-1, TXAS, andHO-1 as compared to control. In certain embodiments, administration ofADAMTS13 results in reduced expression, level, and of ICAM-1 as comparedto control. In certain embodiments, administration of ADAMTS13 resultsin reduced expression and/or level of ET-1 as compared to control. Incertain embodiments, administration of ADAMTS13 results in reducedexpression and/or level of TXAS as compared to control. In certainembodiments, administration of ADAMTS13 results in reduced expressionand/or level of HO-1 as compared to control. In certain embodiments,administration of ADAMTS13 results in reduced ratio of P-NF-kB/NF-kB ascompared to control. In certain embodiments, administration of ADAMTS13results in a reduction of at least one of P-NF-kB/NF-kB ratio, ET-1expression and/or level, TXAS expression and/or level, and HO-1expression and/or level as compared to control. In certain embodiments,administration of ADAMTS13 results in a reduction of P-NF-kB/NF-kBratio, ET-1 expression and/or level, TXAS expression and/or level, andHO-1 expression and/or level as compared to control.

In certain embodiments, administration of ADAMTS13 results in theamelioration of the increase of neutrophil number in the blood ascompared to control.

In certain embodiments, administration of ADAMTS13 results in a decreasein at least one of the following serum biomarkers as compared tocontrol: surfactant-associated protein (SP)-A, SP-B, SP-D, KL-6/MUC1,IL-1, IL-2, IL-3, IL-6, IL-8, IL-10, IL-15, TNFα, adhesion molecules(e.g., E, L-selectin), MMP-9, LTB4, and Ferritin.

ADAMTS13

In some aspects, the disclosure includes ADAMTS13 (also known as “A13”)and compositions comprising ADAMTS13 in the treatment and prevention ofSCD. In particular aspects, the disclosure includes ADAMTS13 andcompositions comprising ADAMTS13 in the treatment and prevention of VOCin SCD. The ADAMTS13 protease is about a 180 kDa to 200 kDa glycosylatedprotein produced predominantly by the liver. ADAMTS13 is a plasmametalloprotease which cleaves VWF multimers and down regulates theiractivity in platelet aggregation. To date, ADAMTS13 has been associatedwith clotting disorders, such as inherited thrombotic thrombocytopenicpurpura (TTP), acquired TTP, cerebral infarction, myocardial infarction,ischemic/reperfusion injury, deep vein thrombosis, and disseminatedintravascular coagulation (DIC), such as sepsis-related DIC.

All forms of ADAMTS13 known in the art are contemplated for use in themethods and uses of the disclosure. Mature ADAMTS13 has a calculatedmolecular mass of about 145 kDa whereas purified plasma-derived ADAMTS13has an apparent molecular mass of about 180 kDa to 200 kDa, probably dueto post-translational modifications consisting with present consensussequences for 10 potential N-glycosylation sites, and severalO-glycosylation sites and one C-mannosylation site in the TSP1 repeats.

As used herein, “ADAMTS13” refers to a metalloprotease of the ADAMTS (adisintegrin and metalloproteinase with thrombospondin type 1 motifs)family that cleaves VWF between residues Tyr¹⁶⁰⁵ and Met¹⁶⁰⁶. In thecontext of the disclosure, “ADAMTS13”, “A13”, or an “ADAMTS13 protein”embraces any ADAMTS13 protein, for example, ADAMTS13 from a mammal suchas a primate, human (NP620594), monkey, rabbit, pig, bovine (XP610784),rodent, mouse (NP001001322), rat (XP342396), hamster, gerbil, canine,feline, frog (NP001083331), chicken (XP415435), and biologically activederivatives thereof. As used herein, “ADAMTS13”, “A13”, or “ADAMTS13protein” refers to recombinant, natural, or plasma-derived ADAMTS13protein. Mutant and variant ADAMTS13 proteins having activity are alsoembraced, as are functional fragments and fusion proteins of theADAMTS13 proteins. In some aspects, an ADAMTS13 protein furthercomprises a tag that facilitates purification, detection, or both. TheADAMTS13 protein of the disclosure, in some aspects, is further modifiedwith an additional therapeutic moiety or a moiety suitable imaging invitro or in vivo.

ADAMTS13 protein includes any protein or polypeptide with ADAMTS13activity, particularly the ability to cleave the peptide bond betweenresidues Tyr-842 and Met-843 of VWF. Human ADAMTS13 proteins include,without limitation, polypeptides comprising the amino acid sequence ofGenBank accession number NP 620594 (NM139025.3) or a processedpolypeptide thereof, for example a polypeptide in which the signalpeptide (amino acids 1 to 29) and/or propeptide (amino acids 30-74) havebeen removed. In certain aspects, an ADAMTS13 protein refers to apolypeptide comprising an amino acid sequence that is highly similar tothat of NP 620596 (ADAMTS13 isoform 2, preproprotein) or amino acids 75to 1371 of P_620594 (ADAMTS13 isoform 2, mature polypeptide). In yetanother embodiment, ADAMTS13 proteins include polypeptides comprising anamino acid sequence highly similar to that of NP 620595 (ADAMTS13isoform 3, preproprotein) or amino acids 75 to 1340 of NP 620595(ADAMTS13 isoform 1, mature polypeptide). In certain aspects, anADAMTS13 protein includes natural variants with VWF cleaving activityand artificial constructs with VWF cleaving activity. In certainaspects, ADAMTS13 encompasses any natural variants, alternativesequences, isoforms or mutant proteins that retain some basal activity.Many natural variants of human ADAMTS13 are known in the art, and areembraced by the formulations of the disclosure, some of which includemutations selected from R7W, V88M, H96D, R102C, R193W, T196I, H234Q,A250V, R268P, W390C, R398H, Q448E, Q456H, P457L, P475S, C508Y, R528G,P618A, R625H, I673F, R692C, A732V, E740K, A900V, S903L, C908Y, C951G,G982R, C1024G, A1033T, R1095W, R1095W, R1123C, C1213Y, T1226I, G1239V,and R1336W.

Additionally, ADAMTS13 proteins include natural and recombinant proteinsthat have been mutated, for example, by one or more conservativemutations at a non-essential amino acid. Preferably, amino acidsessential to the enzymatic activity of ADAMTS13 will not be mutated.These include, for example, residues known or presumed to be essentialfor metal binding such as residues 83, 173, 224, 228, 234, 281, and 284,and residues found in the active site of the enzyme, e.g., residue 225.Similarly, in the context of the disclosure, ADAMTS13 proteins includealternate isoforms, for example, isoforms lacking amino acids 275 to 305and/or 1135 to 1190 of the full-length human protein.

In some aspects, ADAMTS13 proteins are further modified, for example, bypost-translational modifications (e.g., glycosylation at one or moreamino acids selected from human residues 142, 146, 552, 579, 614, 667,707, 828, 1235, 1354, or any other natural or engineered modificationsite) or by ex vivo chemical or enzymatic modification, includingwithout limitation, glycosylation, modification by water-soluble polymer(e.g., PEGylation, sialylation, HESylation, etc.), tagging, and thelike.

In some aspects, the ADAMTS13 protein is human ADAMTS13 or abiologically active derivative or fragment thereof as described in U.S.Patent Application Publication No. 2011/0229455 and/or in U.S. PatentApplication Publication No. 2014/0271611, each of which are incorporatedherein by reference in their entirety and for all purposes.

In certain aspects, the recombinant ADAMTS13 can be BAX930/SHP655. Incertain aspects, the ADAMTS13 protein includes any protein orpolypeptide with ADAMTS13 activity, particularly the ability to cleavethe peptide bond between residues Tyr-842 and Met-843 of VWF with atleast 70%, at least 75%, at least 80%, at least 85%, at least 90%, atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, or at least 99% sequence homologyto BAX930/SHP655.

Proteolytically active recombinant ADAMTS13 may be prepared byexpression in mammalian cell cultures, as described in Plaimauer et al,(2002, Blood. 15; 100(10):3626-32) and US 2005/0266528, the disclosuresof which are herein incorporated by reference in their entireties forall purposes. Methods for the expression of recombinant ADAMTS13 in cellculture are disclosed in Plaimauer B, Scheiflinger F. (Semin Hematol.2004 January; 41(1):24-33 and US 2011/0086413, the disclosures of whichare herein incorporated by reference in their entireties for allpurposes. See also, WO2012/006594, incorporated by reference in theirentireties for all purposes, for methods of producing recombinantADAMTS13 in cell culture.

Methods for purifying ADAMTS13 protein from a sample are described inU.S. Pat. No. 8,945,895, which is incorporated herein by reference forall purposes. Such methods include, in some aspects, enriching forADAMTS13 protein by chromatographically contacting the sample withhydroxyapatite under conditions that allow ADAMTS13 protein to appear inthe eluate or supernatant from the hydroxyapatite. The methods mayfurther comprise tandem chromatography with a mixed mode cationexchange/hydrophobic interaction resin that binds ADAMTS13 protein.Additional optional steps involve ultrafiltration/diafiltration, anionexchange chromatography, cation exchange chromatography, and viralinactivation. In some aspects, such methods include inactivating viruscontaminants in protein samples, where the protein is immobilized on asupport. Also provided herein, in some aspects, are compositions ofADAMTS13 prepared according to the methods described in U.S. Pat. No.8,945,895.

ADAMTS13 Compositions and Administration

In aspects of the disclosure, ADAMTS13 is administered to a subject inneed thereof. To administer ADAMTS13 described herein to a subject,ADAMTS13 is, in some aspects, formulated in a composition comprising oneor more pharmaceutically acceptable carriers.

The term “pharmaceutically acceptable,” as used in connection withcompositions described herein, refers to molecular entities and otheringredients of such compositions that are physiologically tolerable anddo not typically produce untoward reactions when administered to amammal (e.g., a human). Preferably, the term “pharmaceuticallyacceptable” means approved by a regulatory agency of the Federal or astate government or listed in the U.S. Pharmacopeia or other generallyrecognized pharmacopeia for use in mammals, and more particularly inhumans. “Pharmaceutically acceptable carriers” include any and allclinically useful solvents, dispersion media, coatings, antibacterialand antifungal agents, isotonic and absorption delaying agents and thelike. In some aspects, the composition forms solvates with water orcommon organic solvents. Such solvates are included as well.

In some aspects, the disclosure provides stabilized formulations ofplasma derived ADAMTS13 and recombinant ADAMTS13 (rADAMTS13) proteins asdescribed in U.S. Patent Application Publication No. 2011/0229455 (nowU.S. Pat. No. 8,623,352) and/or in U.S. Patent Application PublicationNo. 2014/0271611, both of which are incorporated herein by reference forall purposes. In some embodiments, the formulations provided hereinretain significant ADAMTS13 activity when stored for extended periods oftime. In some embodiments, the formulations of the disclosure reduce orretard dimerization, oligomerization, and/or aggregation of an ADAMTS13protein.

In some aspects, the disclosure provides formulations of ADAMTS13comprising a therapeutically effective amount or dose of an ADAMTS13protein, a sub-physiological to physiological concentration of apharmaceutically acceptable salt, a stabilizing concentration of one ormore sugars and/or sugar alcohols, a non-ionic surfactant, a bufferingagent providing a neutral pH to the formulation, and optionally acalcium and/or zinc salt. Generally, the stabilized ADAMTS13formulations provided herein are suitable for pharmaceuticaladministration. In some aspects, the ADAMTS13 protein is human ADAMTS13or a biologically active derivative or fragment thereof as described inU.S. Patent Application Publication No. 2011/0229455 and/or in U.S.Patent Application Publication No. 2014/0271611, each of which areincorporated herein by reference in their entirety and for all purposes.

In some aspects, the ADAMTS13 formulations are liquid or lyophilizedformulations. In other embodiments, a lyophilized formulation islyophilized from a liquid formulation as described in U.S. PatentApplication Publication No. 2011/0229455 and/or in U.S. PatentApplication Publication No. 2014/0271611, each of which are incorporatedherein by reference in their entirety and for all purposes. In certainembodiments of the formulations provided herein, the ADAMTS13 protein isa human ADAMTS13 or recombinant human ADAMTS13, or a biologically activederivative or fragment thereof as described in U.S. Patent ApplicationPublication No. 2011/0229455 and/or in U.S. Patent ApplicationPublication No. 2014/0271611, each of which are incorporated herein byreference in their entirety and for all purposes.

The composition of the disclosure is, in various aspects, administeredorally, topically, transdermally, parenterally, by inhalation spray,vaginally, rectally, or by intracranial injection. The term parenteralas used herein includes subcutaneous injections, intravenous,intramuscular, intracisternal injection, or infusion techniques. In someembodiments, administration is subcutaneous. Administration byintravenous, intradermal, intramuscular, intramammary, intraperitoneal,intrathecal, retrobulbar, intrapulmonary injection and or surgicalimplantation at a particular site is contemplated as well. In someembodiments, administration is intravenous. Generally, compositions areessentially free of pyrogens, as well as other impurities that could beharmful to the recipient.

Formulation of the composition or pharmaceutical composition will varyaccording to the route of administration selected (e.g., solution oremulsion). An appropriate composition comprising the composition to beadministered is prepared in a physiologically acceptable vehicle orcarrier. For solutions or emulsions, suitable carriers include, forexample, aqueous or alcoholic/aqueous solutions, emulsions orsuspensions, including saline and buffered media. Parenteral vehicles,in some aspects, include sodium chloride solution, Ringer's dextrose,dextrose and sodium chloride, lactated Ringer's or fixed oils.Intravenous vehicles, in certain aspects, include various additives,preservatives, or fluid, nutrient or electrolyte replenishers.

Compositions or pharmaceutical compositions useful in the compounds andmethods of the disclosure containing ADAMTS13 as an active ingredientcontain, in various aspects, pharmaceutically acceptable carriers oradditives depending on the route of administration. Examples of suchcarriers or additives include water, a pharmaceutical acceptable organicsolvent, collagen, polyvinyl alcohol, polyvinylpyrrolidone, acarboxyvinyl polymer, carboxymethylcellulose sodium, polyacrylic sodium,sodium alginate, water-soluble dextran, carboxymethyl starch sodium,pectin, methyl cellulose, ethyl cellulose, xanthan gum, gum Arabic,casein, gelatin, agar, diglycerin, glycerin, propylene glycol,polyethylene glycol, Vaseline, paraffin, stearyl alcohol, stearic acid,human serum albumin (HSA), mannitol, sorbitol, lactose, apharmaceutically acceptable surfactant and the like. Additives used arechosen from, but not limited to, the above or combinations thereof, asappropriate, depending on the dosage form.

A variety of aqueous carriers, e.g., water, buffered water, 0.4% saline,0.3% glycine, or aqueous suspensions contain, in various aspects, theactive compound in admixture with excipients suitable for themanufacture of aqueous suspensions. Such excipients are suspendingagents, for example sodium carboxymethylcellulose, methylcellulose,hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gumtragacanth and gum acacia; dispersing or wetting agents, in someinstances, are a naturally-occurring phosphatide, for example lecithin,or condensation products of an alkylene oxide with fatty acids, forexample polyoxyethylene stearate, or condensation products of ethyleneoxide with long chain aliphatic alcohols, for exampleheptadecaethyl-eneoxycetanol, or condensation products of ethylene oxidewith partial esters derived from fatty acids and a hexitol such aspolyoxyethylene sorbitol monooleate, or condensation products ofethylene oxide with partial esters derived from fatty acids and hexitolanhydrides, for example polyethylene sorbitan monooleate. The aqueoussuspensions, in some aspects, contain one or more preservatives, forexample ethyl, or n-propyl, p-hydroxybenzoate.

In some aspects, ADAMTS13 or ADAMTS13 compositions are lyophilized forstorage and reconstituted in a suitable carrier prior to use. Anysuitable lyophilization and reconstitution techniques known in the artare employed. It is appreciated by those skilled in the art thatlyophilization and reconstitution leads to varying degrees of proteinactivity loss and that use levels are often adjusted to compensate.

Dispersible powders and granules suitable for preparation of an aqueoussuspension by the addition of water provide the active compound inadmixture with a dispersing or wetting agent, suspending agent and oneor more preservatives. Suitable dispersing or wetting agents andsuspending agents are exemplified by those already mentioned above.

In some embodiments, the ADAMTS13 formulations provided herein mayfurther comprise one or more pharmaceutically acceptable excipients,carriers, and/or diluents as described in U.S. Patent ApplicationPublication No. 2011/0229455 and/or in U.S. Patent ApplicationPublication No. 2014/0271611, each of which are incorporated herein byreference in their entirety and for all purposes.

In some embodiments, the ADAMTS13 formulations provided herein will havea tonicity in a range described in as described in U.S. PatentApplication Publication No. 2011/0229455 and/or in U.S. PatentApplication Publication No. 2014/0271611, each of which are incorporatedherein by reference in their entirety and for all purposes.

In some aspects, the disclosure provides formulations of ADAMTS13comprising the exemplary formulations described in Section III(“ADAMTS13 Compositions and Formulations”) of U.S. Patent ApplicationPublication No. 2011/0229455. The methods of ADAMTS13 production andcompositions thereof as described in U.S. Patent Application PublicationNo. 2011/0229455 and/or in U.S. Patent Application Publication No.2014/0271611 are incorporated herein by reference in their entirety forall purposes. Additionally, actual methods for preparing parenterallyadministrable formulations and compositions are known or are apparent tothose skilled in the art and are described in more detail in, forexample, Remington's Pharmaceutical Science, 15th ed., Mack PublishingCompany, Easton, Pa. (1980).

In various aspects, the pharmaceutical compositions are in the form of asterile injectable aqueous, oleaginous suspension, dispersions orsterile powders for the extemporaneous preparation of sterile injectablesolutions or dispersions. The suspension, in some aspects, is formulatedaccording to the known art using those suitable dispersing or wettingagents and suspending agents which have been mentioned above. Thesterile injectable preparation, in certain aspects, is a sterileinjectable solution or suspension in a non-toxic parenterally-acceptablediluent or solvent, for example as a solution in 1,3-butane diol. Insome embodiments, the carrier is a solvent or dispersion mediumcontaining, for example, water, ethanol, polyol (for example, glycerol,propylene glycol, and liquid polyethylene glycol, and the like),suitable mixtures thereof, vegetable oils, Ringer's solution andisotonic sodium chloride solution. In addition, sterile, fixed oils areconventionally employed as a solvent or suspending medium. For thispurpose any bland fixed oil is employed, in various aspects, includingsynthetic mono- or diglycerides. In addition, fatty acids such as oleicacid find use in the preparation of injectables.

In all cases the form must be sterile and must be fluid to the extentthat easy syringability exists. The proper fluidity is maintained, forexample, by the use of a coating, such as lecithin, by the maintenanceof the required particle size in the case of dispersion and by the useof surfactants. It must be stable under the conditions of manufactureand storage and must be preserved against the contaminating action ofmicroorganisms, such as bacteria and fungi. The prevention of the actionof microorganisms is brought about by various antibacterial andantifungal agents, for example, parabens, chlorobutanol, phenol, sorbicacid, thimerosal, and the like. In many cases, it will be desirable toinclude isotonic agents, for example, sugars or sodium chloride. Incertain aspects, prolonged absorption of the injectable compositions isbrought about by the use in the compositions of agents delayingabsorption, for example, aluminum monostearate and gelatin.

Compositions useful for administration, in certain aspects, areformulated with uptake or absorption enhancers to increase theirefficacy. Such enhancers include, for example, salicylate,glycocholate/linoleate, glycholate, aprotinin, bacitracin, SDS, caprateand the like. See, e.g., Fix (J. Pharm. Sci., 85:1282-1285, 1996) andOliyai et al. (Ann. Rev. Pharmacol. Toxicol., 32:521-544, 1993), each ofwhich are incorporated herein by reference in their entirety and for allpurposes.

In addition, the properties of hydrophilicity and hydrophobicity of thecompositions used in the compositions and methods of the disclosure arewell balanced, thereby enhancing their utility for both in vitro andespecially in vivo uses, while other compositions lacking such balanceare of substantially less utility. Specifically, compositions in thedisclosure have an appropriate degree of solubility in aqueous mediawhich permits absorption and bioavailability in the body, while alsohaving a degree of solubility in lipids which permits the compounds totraverse the cell membrane to a putative site of action.

In particular aspects, ADAMTS13 is provided in a pharmaceuticallyacceptable (i.e., sterile and non-toxic) liquid, semisolid, or soliddiluent that serves as a pharmaceutical vehicle, excipient, or medium.Any diluent known in the art is used. Exemplary diluents include, butare not limited to, polyoxyethylene sorbitan monolaurate, magnesiumstearate, methyl- and propylhydroxybenzoate, talc, alginates, starches,lactose, sucrose, dextrose, sorbitol, mannitol, gum acacia, calciumphosphate, mineral oil, cocoa butter, and oil of theobroma.

The composition is packaged in forms convenient for delivery. Thecomposition is enclosed within a capsule, caplet, sachet, cachet,gelatin, paper, or other container. These delivery forms are preferredwhen compatible with delivery of the composition into the recipientorganism and, particularly, when the composition is being delivered inunit dose form. The dosage units are packaged, e.g., in vials, tablets,capsules, suppositories, or cachets.

The disclosure includes methods for treating, ameliorating, and/orpreventing VOC in SCD in a subject, including administering an effectiveamount of ADAMTS13 or an ADAMTS13 composition as described herein. Thecomposition is introduced into the subject to be treated by anyconventional method as described herein in detail above. In certainaspects, the composition is administered in a single dose or a pluralityof doses over a period of time (as described in more detail below).

In some embodiments, the composition comprising ADAMTS13 is administeredto the subject within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 60,72, 84, 96, 108, or 120 hours after the onset of the VOC. In someembodiments, the composition comprising ADAMTS13 is administered to thesubject within about 1-2 hours, about 1-5 hours, about 1-10 hours, about1-12 hours, about 1-24 hours, about 1-36 hours, about 1-48 hour, about1-60 hours, about 1-72 hours, about 1-84 hours, about 1-96 hours, about1-108 hours, or about 1-120 hours after the onset of the VOC. In someembodiments, the composition comprising ADAMTS13 is administered to thesubject within about 2-5 hours, about 5-10 hours, about 10-20 hours,about 20-40 hours, about 30-60 hours, about 40-80 hours, about 50-100hours, or about 60-120 hours after the onset of the VOC. In someembodiments, the composition is administered within 1 week of the VOC.In some embodiments, the composition is administered daily after theVOC. In some embodiments, the composition is administered weekly afterthe VOC. In some embodiments, the composition is administered every day.In some embodiments, the composition is administered every other day. Insome embodiments, the composition is administered every third day. Insome embodiments, the composition is administered twice a week. In someembodiments, the composition is administered until the clinicalmanifestations (e.g., symptoms and/or biomarkers) resolve. In someembodiments, the composition is administered until a day after clinicalmanifestations resolve. In some embodiments, the composition isadministered for at least two days after clinical manifestationsresolve. In some embodiments, the composition is administered for atleast three days after clinical manifestations resolve. In someembodiments, the composition is administered for at least a week afterclinical manifestations resolve.

In some aspects, the composition comprising ADAMTS13 is administered tothe subject to prevent the onset of VOC. In such preventative treatment,ADAMTS13 is administered in a singular bolus injection or in multipledoses to maintain a circulating level of ADAMTS13 effective to preventthe onset of the VOC. In such aspects, the composition comprisingADAMTS13 is administered monthly, every two weeks, weekly, twice a week,every other day, or daily. In particular aspects, the injection isadministered subcutaneously. In other aspects, the injection isadministered intravenously.

In some embodiments, the composition comprising ADAMTS13 is administeredto the subject before the onset of the VOC to prevent the VOC. In suchaspects of the disclosure, the composition is administered in atherapeutically effective amount or dose sufficient to maintain aneffective level of ADAMTS13 activity in the subject or in the blood ofthe subject.

The disclosure includes methods for treating, ameliorating, orpreventing ALI or ARDS in a subject, including administering aneffective amount of ADAMTS13 or an ADAMTS13 composition as describedherein. The composition is introduced into the subject to be treated byany conventional method as described herein in detail above. In certainaspects, the composition is administered in a single dose or a pluralityof doses over a period of time (as described in more detail below).

In some embodiments, the composition comprising ADAMTS13 is administeredto the subject within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 60, 72, 84,96, 108, or 120 hours after the onset of the ALI or ARDS. In someembodiments, the composition comprising ADAMTS13 is administered to thesubject within about 1-2 hours, about 1-5 hours, about 1-10 hours, about1-12 hours, about 1-24 hours, about 1-36 hours, about 1-48 hour, about1-60 hours, about 1-72 hours, about 1-84 hours, about 1-96 hours, about1-108 hours, or about 1-120 hours after the onset of the ALI or ARDS. Insome embodiments, the composition comprising ADAMTS13 is administered tothe subject within about 2-5 hours, about 5-10 hours, about 10-20 hours,about 20-40 hours, about 30-60 hours, about 40-80 hours, about 50-100hours, or about 60-120 hours after the onset of the ALI or ARDS. In someembodiments, the composition is administered within 4 hours, within 8hours, within 12 hours, within 1 day, within 2 days, within 3 days,within 4 days, within 5 days, within 6 days after the onset or diagnosisof the ALI or ARDS. In some embodiments, the composition is administeredwithin 1 week after the onset or diagnosis of the ALI or ARDS. In someembodiments, the composition is administered daily after the onset ordiagnosis of ALI or ARDS. In some embodiments, the composition isadministered weekly after the onset or diagnosis of ALI or ARDS. In someembodiments, the composition is administered every day. In someembodiments, the composition is administered every other day. In someembodiments, the composition is administered every third day. In someembodiments, the composition is administered twice a week. In someembodiments, the composition is administered until the clinicalmanifestations resolve. In some embodiments, the composition isadministered until a day after clinical manifestations resolve. In someembodiments, the composition is administered for at least two days afterclinical manifestations resolve. In some embodiments, the composition isadministered for at least three days after clinical manifestationsresolve. In some embodiments, the composition is administered for atleast a week after clinical manifestations resolve.

In some aspects, the composition comprising ADAMTS13 is administered tothe subject to prevent the onset of ALI or ARDS. In such preventativetreatment, ADAMTS13 is administered in a singular bolus injection or inmultiple doses to maintain a circulating level of ADAMTS13 effective toprevent the onset of the ALI or ARDS. In such aspects, the compositioncomprising ADAMTS13 is administered monthly, every two weeks, weekly,twice a week, every other day, or daily. In particular aspects, theinjection is administered subcutaneously. In other aspects, theinjection is administered intravenously.

In some embodiments, the composition comprising ADAMTS13 is administeredto the subject before the onset of the ALI or ARDS to prevent the ALI orARDS. In such aspects of the disclosure, the composition is administeredin a therapeutically effective amount or dose sufficient to maintain aneffective level of ADAMTS13 activity in the subject or in the blood ofthe subject.

Dosing of ADAMTS13 Compositions/Methods of Treating

In various aspects, the effective dosage of ADAMTS13 or an ADAMTS13composition to be administered varies depending on multiple factorswhich modify the action of drugs, e.g. the age, condition, body weight,sex, and diet of the subject, the severity of any infection, time ofadministration, mode of administration, and other clinical factors,including the severity of the VOC of the SCD.

In some aspects, formulations or compositions of the disclosure areadministered by an initial bolus followed by booster delivery after aperiod of time has elapsed. In certain aspects, formulations of thedisclosure are administered by an initial bolus followed by a continuousinfusion to maintain therapeutic circulating levels of ADAMTS13. Inparticular aspects, ADAMTS13 or an ADAMTS13 composition of thedisclosure is administered over extended periods of time. In someaspects, the ADAMTS13 or ADAMTS13 composition is delivered in a rapidtreatment regimen to relieve acute symptoms of VOC. In some aspects, theADAMTS13 or ADAMTS13 composition is delivered in a prolonged and variedtreatment regimen to prevent the occurrence of VOC. As another example,the composition or formulation of the disclosure is administered as aone-time dose. Those of ordinary skill in the art readily optimizeeffective dosages and administration regimens as determined by goodmedical practice and the clinical condition of the individual subject.The frequency of dosing depends on the pharmacokinetic parameters of theagents, the route of administration, and the condition of the subject.

The pharmaceutical formulation is determined by one skilled in the artdepending upon the route of administration and desired dosage. See forexample, Remington's Pharmaceutical Sciences, 18th Ed. (1990, MackPublishing Co., Easton, Pa. 18042) pages 1435-1712, the disclosure ofwhich is hereby incorporated by reference for all purposes. Suchformulations, in some instances, influence the physical state,stability, rate of in vivo release, and rate of in vivo clearance of theadministered composition. Depending on the route of administration, asuitable dose is calculated, in particular aspects, according to bodyweight, body surface area or organ size. In some aspects, appropriatedosages are ascertained through use of established assays fordetermining blood level dosages in conjunction with appropriatedose-response data. In certain aspects, the antibody titer of anindividual is measured to determine optimal dosage and administrationregimens. The final dosage regimen will be determined by the attendingdoctor or physician, considering various factors which modify the actionof the pharmaceutical compositions, e.g. the composition's specificactivity, the responsiveness of the subject, the age, condition, bodyweight, sex and diet of the subject, the severity of any infection ormalignant condition, time of administration and other clinical factors,including the severity of the pain or the VOC.

In certain aspects, the ADAMTS13 or ADAMTS13 composition comprises anydose of ADAMTS13 sufficient to evoke a response in the subject. In someembodiments, the dose of ADAMTS13 is sufficient to treat VOC. In someembodiments, the dose of ADAMTS13 is sufficient to prevent VOC. In someembodiments, the dose of ADAMTS13 is sufficient to treat ALI. In someembodiments, the dose of ADAMTS13 is sufficient to prevent ALI. In someembodiments, the dose of ADAMTS13 is sufficient to treat ARDS. In someembodiments, the dose of ADAMTS13 is sufficient to prevent ARDS. Theeffective amount of ADAMTS13 or ADAMTS13 composition to be employedtherapeutically will depend, for example, upon the therapeutic contextand objectives. One skilled in the art will appreciate that theappropriate dosage levels for treatment or prevention will thus varydepending, in part, upon the molecule delivered, the indication forwhich the ADAMTS13 or ADAMTS13 composition is being used, the route ofadministration, and the size (body weight, body surface or organ size)and condition (the age and general health) of the patient. Accordingly,the clinician, in some instances, titers the dosage and modifies theroute of administration to obtain the optimal therapeutic effect.

Dosage, unless otherwise specifically recited, is provided ininternational units. As discussed herein below, the use of internationalunits (IU) is the new standard for measuring ADAMTS13 activity. Up untilrecently, FRETS units (or FRETS test units) were the standard formeasuring ADAMTS13 activity. 20 FRETS units (FRETS U) is equivalent toapproximately 21.78 IU. In other words, 20 IU of ADAMTS13 is equivalentto about 18.22 FRETS U of ADAMTS13.

A typical dosage, in various aspects, ranges from about 10 internationalunits per kilogram body weight up to about 10,000 international unitsper kilogram body weight. In some aspects, a dosage or therapeuticallyeffective amount of ADAMTS13 is up to about 10,000 international unitsper kilogram body weight or more, depending on the factors mentionedabove. In other aspects, the dosage may range from about 20 to about6,000 international units per kilogram body weight. In some aspects, thedosage or therapeutically effective amount of ADAMTS13 is from about 40to about 4,000 international units per kilogram body weight. In someaspects, the dosage or therapeutically effective amount is from about100 to about 3,000 international units per kilogram body weight.

In particular aspects, the dosage or therapeutically effective amount isfrom about 10 to about 500 international units per kilogram body weight.In some aspects, the dosage or therapeutically effective amount is fromabout 50 to about 450 international units per kilogram body weight. Insome aspects, the therapeutically effective amount is from about 40 toabout 100 international units per kilogram body weight. In some aspects,the therapeutically effective amount is from about 40 to about 150international units per kilogram body weight. In some aspects, thedosage or therapeutically effective amount is from about 100 to about500 international units per kilogram body weight. In some aspects, thedosage or therapeutically effective amount is from about 100 to about400 international units per kilogram body weight. In some aspects, thedosage or therapeutically effective amount is from about 100 to about300 international units per kilogram body weight. In some aspects, thedosage or therapeutically effective amount is from about 300 to about500 international units per kilogram body weight. In some aspects, thedosage or therapeutically effective amount is from about 200 to about300 international units per kilogram body weight. In some aspects, thedosage or therapeutically effective amount is about 100, about 150,about 200, about 250, about 300, about 350, about 400, about 450, orabout 500 international units per kilogram body weight.

In further aspects, the dosage or therapeutically effective amount isfrom about 50 to about 1,000 international units per kilogram bodyweight. In some aspects, the dosage or therapeutically effective amountis from about 100 to about 900 international units per kilogram bodyweight. In some aspects, the dosage or therapeutically effective amountis from about 200 to about 800 international units per kilogram bodyweight. In some aspects, the dosage or therapeutically effective amountis from about 300 to about 700 international units per kilogram bodyweight. In some aspects, the dosage or therapeutically effective amountis from about 400 to about 600 international units per kilogram bodyweight. In some aspects, the dosage or therapeutically effective amountis about 500 international units per kilogram body weight.

In some aspects, the dosage or therapeutically effective amount is about10 international units per kilogram body weight, about 20 internationalunits per kilogram body weight, about 30 international units perkilogram body weight, about 40 international units per kilogram bodyweight, about 50 international units per kilogram body weight, about 60international units per kilogram body weight, about 70 internationalunits per kilogram body weight, about 80 international units perkilogram body weight, about 90 international units per kilogram bodyweight, about 100 international units per kilogram body weight, about120 international units per kilogram body weight, about 140international units per kilogram body weight, about 150 internationalunits per kilogram body weight, about 160 international units perkilogram body weight, about 180 international units per kilogram bodyweight, about 200 international units per kilogram body weight, about220 international units per kilogram body weight, about 240international units per kilogram body weight, about 250 internationalunits per kilogram body weight, about 260 international units perkilogram body weight, about 280 international units per kilogram bodyweight, about 300 international units per kilogram body weight, about350 international units per kilogram body weight, about 400international units per kilogram body weight, about 450 internationalunits per kilogram body weight, about 500 international units perkilogram body weight, about 550 international units per kilogram bodyweight, about 600 international units per kilogram body weight, about650 international units per kilogram body weight, about 700international units per kilogram body weight, about 750 internationalunits per kilogram body weight, about 800 international units perkilogram body weight, about 850 international units per kilogram bodyweight, about 900 international units per kilogram body weight, about950 international units per kilogram body weight, about 1,000international units per kilogram body weight, about 1,100 internationalunits per kilogram body weight, about 1,100 international units perkilogram body weight, about 1,200 international units per kilogram bodyweight, about 1,300 international units per kilogram body weight, about1,400 international units per kilogram body weight, about 1,500international units per kilogram body weight, about 1,600 internationalunits per kilogram body weight, about 1,800 international units perkilogram body weight, about 2,000 international units per kilogram bodyweight, about 2,500 international units per kilogram body weight, about3,000 international units per kilogram body weight, about 3,500international units per kilogram body weight, about 4,000 internationalunits per kilogram body weight, about 4,500 international units perkilogram body weight, about 5,000 international units per kilogram bodyweight, about 5,500 international units per kilogram body weight, about6,000 international units per kilogram body weight, about 6,500international units per kilogram body weight, about 7,000 internationalunits per kilogram body weight, about 7,500 international units perkilogram body weight, about 8,000 international units per kilogram bodyweight, about 8,500 international units per kilogram body weight, about9,000 international units per kilogram body weight, about 9,500international units per kilogram body weight, and about 10,000international units per kilogram body weight.

As used herein, “one unit of ADAMTS13 activity” or “one activity unit”is defined as the amount of activity in 1 mL of pooled normal humanplasma, regardless of the assay being used. As provided above, however,the new standard for measuring or dosing ADAMTS13 is international units(IU). 20 FRETS test units or 20 FRETS units (FRETS U) is equivalent toapproximately 21.78 IU. In other words, 20 IU of ADAMTS13 is equivalentto about 18.22 FRETS U of ADAMTS13. Thus, the change to the new standardresults in an approximate shift of 8.9% in the conversion of FRETS U toIU.

In some aspects, Fluorescence Resonance Energy Transfer (FRETS) assaysare used to measure ADAMTS13 activity. FRETS requires two interactingpartners of which one is labeled with a donor fluorophore and the otheris labeled with an acceptor fluorophore. FRETS assays for ADAMTS13involve a chemically modified fragment of the A2 domain of VWF whichspans the ADAMTS13 cleavage site. This is readily cleaved by normalplasma but not by ADAMTS13 deficient plasma. This cleavage is blocked byEDTA and so samples for this assay must be collected into tubes thatcontain citrate as an anticoagulant and not EDTA. One unit of ADAMTS13FRETS-VWF73 activity is the amount of activity needed to cleave the sameamount of FRETS-VWF73 substrate (Kokame et al., Br J. Haematol. 2005April; 129(1):93-100, incorporated herein by reference) as is cleaved byone mL of pooled normal human plasma.

In some aspects, additional activity assays are used for measuring theactivity of ADAMTS13. For example, direct ADAMTS13 activity assays canbe performed to detect the cleavage of either full-length VWF moleculesor VWF fragments using SDS agarose gel electrophoresis and indirectdetection of ADAMTS13 activity can be detected with collagen bindingassays. Direct assays, including the FRETS assay, as described herein,involve the detection of cleavage of products either of a full-lengthVWF molecule or a VWF fragment that encompasses the ADAMTS13 cleavagesite. With SDS Agarose Gel electrophoresis and Western Blotting,purified VWF is incubated with plasma for 24 hours. Cleavage of the VWFby ADAMTS13 takes place leading to a reduction in multimer sizes. Thisreduction is visualized by agarose gel electrophoresis followed byWestern blotting with a peroxidase-conjugated anti-VWF antibody. Theconcentration of ADAMTS13 activity in the test sample can be establishedby reference to a series of diluted normal plasma samples. SDS-PAGE andWestern Blotting can also be carried out, which involves thevisualization of dimeric VWF fragments following SDS PAGE and WesternBlotting. The assay is technically easier than SDS agarose gelelectrophoresis and appears a very sensitive method for measuringADAMTS13 activity levels.

In some aspects, indirect assays involve the detection of cleavage ofproducts either of a full-length VWF molecule or a VWF fragment thatencompasses the ADAMTS13 cleavage site in the A2 domain of VWF. Suchassays include collagen binding assays, where normal plasma or purifiedVWF is incubated with the test plasma sample in the presence of BaCl2and 1.5M urea which denatures the VWF. VWF is cleaved by ADAMTS13 andresidual VWF is measured by its binding to collagen Type III. The boundVWF is quantitated using an ELISA assay with a conjugated anti-VWFantibody. Another indirect assay is the ristocetin-induced aggregationassay. This is similar to the collagen-binding assay above but residualVWF is measured by ristocetin-induced platelet aggregation using aplatelet aggregometer. Another indirect assay is a functional ELISA. Inthis assay, a recombinant VWF fragment is immobilized onto an ELISAplate using an antibody to a tag on the VWF. The VWF fragment encodesthe A2 domain and the ADAMTS13 cleavage site at Tyr1605-Met1606 and istagged with S-transferase [GST]-histidine [GST-VWF73-His]. Plasma isadded to the immobilized GST-VWF73-His fragment and cleavage of theimmobilized fragment occurs at the ADAMTS13 cleavage site. The residual,cleaved VWF fragment is measured by using a second monoclonal antibodythat recognizes only the cleaved VWF fragment and NOT the interactfragment. ADAMTS13 activity is, therefore, inversely proportional to theresidual substrate concentration.

In certain embodiments, ADAMTS13 is provided or administered in atherapeutically effective concentration between about 0.05 mg/mL andabout 10 mg/mL in the final formulation. In other embodiments, ADAMTS13is present at a concentration of between about 0.1 mg/mL and about 10mg/mL. In yet other embodiments, ADAMTS13 is present at a concentrationof between about 0.1 mg/mL and about 5 mg/mL. In another embodiment,ADAMTS13 is present at a concentration of between about 0.1 mg/mL andabout 2 mg/mL. In yet other embodiments, ADAMTS13 may be present atabout 0.01 mg/mL, or at about 0.02 mg/mL, 0.03 mg/mL, 0.04 mg/mL, 0.05mg/mL, 0.06 mg/mL, 0.07 mg/mL, 0.08 mg/mL, 0.09 mg/mL, 0.1 mg/mL, 0.2mg/mL, 0.3 mg/mL, 0.4 mg/mL, 0.5 mg/mL, 0.6 mg/mL, 0.7 mg/mL, 0.8 mg/mL,0.9 mg/mL, 1.0 mg/mL, 1.1 mg/mL, 1.2 mg/mL, 1.3 mg/mL, 1.4 mg/mL, 1.5mg/mL, 1.6 mg/mL, 1.7 mg/mL, 1.8 mg/mL, 1.9 mg/mL, 2.0 mg/mL, 2.5 mg/mL,3.0 mg/mL, 3.5 mg/mL, 4.0 mg/mL, 4.5 mg/mL, 5.0 mg/mL, 5.5 mg/mL, 6.0mg/mL, 6.5 mg/mL, 7.0 mg/mL, 7.5 mg/mL, 8.0 mg/mL, 8.5 mg/mL, 9.0 mg/mL,9.5 mg/mL, 10.0 mg/mL, or a higher concentration.

In some embodiments, the concentration of a relatively pure ADAMTS13formulation may be determined by spectroscopy (i.e., total proteinmeasured at A280) or other bulk determination (e.g., Bradford assay,silver stain, weight of a lyophilized powder, etc.). In otherembodiments, the concentration of ADAMTS13 may be determined by anADAMTS13 ELISA assay (e.g., mg/mL antigen).

In some aspects, the concentration of ADAMTS13 in a formulation of thedisclosure is expressed as a level of enzymatic activity. For example,in some embodiments, an ADAMTS13 formulation contains between about 10units of FRETS-VWF73 activity and about 10,000 units of FRETS-VWF73activity or other suitable ADAMTS13 enzymatic unit (IU). In otherembodiments, the formulation may contain between about 20 units ofFRETS-VWF73 (U_(FV73)) activity and about 8,000 units of FRETS-VWF73activity, or between about 30 U_(FV73) and about 6,000 U_(FV73), orbetween about 40 U_(FV73) and about 4,000 U_(FV73), or between about 50U_(FV73) and about 3,000 U_(FV73), or between about 75 U_(FV73) andabout 2,500 U_(FV73), or between about 100 U_(FV73) and about 2,000U_(FV73), or between about 200 U_(FV73) and about 1,500 U_(FV73), orbetween about other ranges therein.

In some embodiments, ADAMTS13 is provided or administered at a dose offrom about 10 U_(FV73)/kg body weight to 10,000 U_(FV73)/kg body weight.In one embodiment, ADAMTS13 is administered at a dose of from about 20U_(FV73)/kg body weight to about 8,000 U_(FV73)/kg body weight. In oneembodiment, ADAMTS13 is administered at a dose of from about 30U_(FV73)/kg body weight to about 6,000 U_(FV73)/kg body weight. In oneembodiment, ADAMTS13 is administered at a dose of from about 40U_(FV73)/kg body weight to about 4,000 U_(FV73)/kg body weight. In oneembodiment, ADAMTS13 is administered at a dose of from about 100U_(FV73)/kg body weight to about 3,000 U_(FV73)/kg body weight. In oneembodiment, ADAMTS13 is administered at a dose of from about 200U_(FV73)/kg body weight to about 2,000 U_(FV73)/kg body weight. In otherembodiments, ADAMTS13 is administered at about 10 U_(FV73)/kg bodyweight, about 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300,350, 400, 450, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300,1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300,2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300,3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, 4,500, 5,000, 5,500,6,000, 6,500, 7,000, 7,500, 8,000, 8,500, 9,000, 9,500, or 10,000U_(FV73)/kg body weight, or at an intermediate dose or dose rangethereof.

In some aspects, an ADAMTS13 formulation provided herein containsbetween about 20 and about 10,000 U_(FV73). In some embodiments, aformulation contains about 10 units of FRETS-VWF73 activity, or about20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450,500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500,1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500,2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500,3,600, 3,700, 3,800, 3,900, 4,000, 4,100, 4,200, 4,300, 4,400, 4,500,4,600, 4,700, 4,800, 4,900, 5,000, 5,100, 5,200, 5,300, 5,400, 5,500,5,600, 5,700, 5,800, 5,900, 6,000, 6,100, 6,200, 6,300, 6,400, 6,500,6,600, 6,700, 6,800, 6,900, 7,000, 7,100, 7,200, 7,300, 7,400, 7,500,7,600, 7,700, 7,800, 7,900, 8,000, 8,100, 8,200, 8,300, 8,400, 8,500,8,600, 8,700, 8,800, 8,900, 9,000, 9,100, 9,200, 9,300, 9,400, 9,500,9,600, 9,700, 9,800, 9,900, 10,000 or more units of FRETS-VWF73activity.

In some aspects, the concentration of ADAMTS13 may be expressed as anenzymatic activity per unit volume, for example, ADAMTS13 enzymaticunits per mL (IU/mL). For example, in some embodiments, an ADAMTS13formulation contains between about 10 IU/mL and about 10,000 IU/mL. Insome other embodiments, the formulation contains between about 20 IU/mLand about 10,000 IU/mL, or between about 20 IU/mL and about 8,000 IU/mL,or between about 30 IU/mL and about 6,000 IU/mL, or between about 40IU/mL and about 4,000 IU/mL, or between about 50 IU/mL and about 3,000IU/mL, or between about 75 IU/mL and about 2,500 IU/mL, or between about100 IU/mL and about 2,000 IU/mL, or between about 200 IU/mL and about1,500 IU/mL, or between about other ranges therein. In some embodiments,an ADAMTS13 formulation provided herein contains between about 150 IU/mLand about 600 IU/mL. In another embodiment, an ADAMTS13 formulationprovided herein contains between about 100 IU/mL and about 1,000 IU/mL.In some embodiments, an ADAMTS13 formulation provided herein containsbetween about 100 IU/mL and about 800 IU/mL. In some embodiments, anADAMTS13 formulation provided herein contains between about 100 IU/mLand about 600 IU/mL. In some embodiments, an ADAMTS13 formulationprovided herein contains between about 100 IU/mL and about 500 IU/mL. Insome embodiments, an ADAMTS13 formulation provided herein containsbetween about 100 IU/mL and about 400 IU/mL. In some embodiments, anADAMTS13 formulation provided herein contains between about 100 IU/mLand about 300 IU/mL. In some embodiments, an ADAMTS13 formulationprovided herein contains between about 100 IU/mL and about 200 IU/mL. Insome embodiments, an ADAMTS13 formulation provided herein containsbetween about 300 IU/mL and about 500 IU/mL. In some embodiments, anADAMTS13 formulation provided herein contains about 100 IU/mL. In someembodiments, an ADAMTS13 formulation provided herein contains about 300IU/mL. In various embodiments, a formulation contains about 10 IU/mL, orabout 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400,450, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500,1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500,2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500,3,600, 3,700, 3,800, 3,900, 4,000, 4,100, 4,200, 4,300, 4,400, 4,500,4,600, 4,700, 4,800, 4,900, 5,000, 5,100, 5,200, 5,300, 5,400, 5,500,5,600, 5,700, 5,800, 5,900, 6,000, 6,100, 6,200, 6,300, 6,400, 6,500,6,600, 6,700, 6,800, 6,900, 7,000, 7,100, 7,200, 7,300, 7,400, 7,500,7,600, 7,700, 7,800, 7,900, 8,000, 8,100, 8,200, 8,300, 8,400, 8,500,8,600, 8,700, 8,800, 8,900, 9,000, 9,100, 9,200, 9,300, 9,400, 9,500,9,600, 9,700, 9,800, 9,900, 10,000 or more IU/mL.

In some embodiments, the ADAMTS13 formulations provided herein mayfurther comprise one or more pharmaceutically acceptable excipients,carriers, and/or diluents as described in U.S. Patent ApplicationPublication No. 2011/0229455 and/or in U.S. Patent ApplicationPublication No. 2014/0271611, each of which incorporated by reference intheir entirety for all purposes. Furthermore, in one embodiment, theADAMTS13 formulations provided herein will have a tonicity in a rangedescribed in as described in U.S. Patent Application Publication No.2011/0229455 and/or in U.S. Patent Application Publication No.2014/0271611, each of which incorporated by reference in their entiretyfor all purposes.

The frequency of dosing will depend upon the pharmacokinetic parametersof the ADAMTS13 molecule in the formulation used. Typically, a clinicianwill administer the composition until a dosage is reached that achievesthe desired effect. The composition, in various aspects, is thereforeadministered as a single dose, or as two or more doses (which may or maynot contain the same amount of the desired molecule) over time, or as acontinuous infusion via an implantation device or catheter. In someaspects, the composition comprising ADAMTS13 is administered in a singlebolus injection, monthly, every two weeks, weekly, twice a week, everyother day, daily, every 12 hours, every eight hours, every six hours,every four hours, or every two hours. In the prophylactic orpreventative treatment aspects of the disclosure, ADAMTS13 isadministered in multiple doses to maintain a circulating level ofADAMTS13 effective to prevent the onset of the VOC, ALI, or ARDS. Insuch aspects, the composition comprising ADAMTS13 is administeredmonthly, every two weeks, weekly, twice a week, every other day, ordaily. In particular aspects, the injection is administeredsubcutaneously (e.g., WO2014151968, incorporated herein by reference inits entirety for all purposes). In other aspects, the injection isadministered intravenously. Further refinement of the appropriate dosageadministered and the timing of administration is routinely made by thoseof ordinary skill in the art and is within the ambit of tasks routinelyperformed by them. Appropriate dosages are often ascertained through useof appropriate dose-response data which is routinely obtained.

Kits Comprising ADAMTS13

As an additional aspect, the disclosure includes kits which comprise oneor more pharmaceutical formulations for administration of ADAMTS13 or anADAMTS13 composition to a subject packaged in a manner which facilitatestheir use for administration to the subject.

In a specific embodiment, the disclosure includes kits for producing asingle dose administration unit. In another embodiment, the disclosureincludes kits for providing multiple dose administration units. Thekits, in various aspects, each contain both a first container having adried protein and a second container having an aqueous formulation. Alsoincluded within the scope of this disclosure are kits containing singleand multi-chambered pre-filled syringes (e.g., liquid syringes andlyosyringes).

In another embodiment, such a kit includes a pharmaceutical formulationdescribed herein (e.g., a composition comprising a therapeutic protein,e.g., ADAMTS13), packaged in a container such as a sealed bottle orvessel, with a label affixed to the container or included in the packagethat describes use of the compound or composition in practicing themethod. In one embodiment, the pharmaceutical formulation is packaged inthe container such that the amount of headspace in the container (e.g.,the amount of air between the liquid formulation and the top of thecontainer) is very small. Preferably, the amount of headspace isnegligible (i.e., almost none).

In some aspects, the pharmaceutical formulation or composition comprisesa stabilizer. The term “stabilizer” refers to a substance or excipientwhich protects the composition from adverse conditions, such as thosewhich occur during heating or freezing, and/or prolongs the stability orshelf-life of the composition or pharmaceutical composition in a stablestate. Examples of stabilizers include, but are not limited to, sugars,such as sucrose, lactose and mannose; sugar alcohols, such as mannitol;amino acids, such as glycine or glutamic acid; and proteins, such ashuman serum albumin or gelatin.

In some aspects, the pharmaceutical formulation or composition comprisesan antimicrobial preservative. The term “antimicrobial preservative”refers to any substance which is added to the composition that inhibitsthe growth of microorganisms that may be introduced upon repeatedpuncture of multidose vials, should such containers be used. Examples ofantimicrobial preservatives include, but are not limited to, substancessuch as thimerosal, 2-phenoxyethanol, benzethonium chloride, and phenol.

In one aspect, the kit contains a first container having a therapeuticprotein or protein composition and a second container having aphysiologically acceptable reconstitution solution for the composition.In one aspect, the pharmaceutical formulation is packaged in a unitdosage form. The kit optionally further includes a device suitable foradministering the pharmaceutical formulation according to a specificroute of administration. In some aspects, the kit contains a label thatdescribes use of the pharmaceutical formulations.

This entire document is intended to be related as a unified disclosure,and it should be understood that all combinations of features describedherein are contemplated, even if the combination of features are notfound together in the same sentence, or paragraph, or section of thisdocument. The disclosure also includes, for instance, all embodiments ofthe disclosure narrower in scope in any way than the variationsspecifically mentioned above.

All publications, patents and patent applications cited in thisspecification are herein incorporated by reference as if each individualpublication or patent application were specifically and individuallyindicated to be incorporated by reference in its entirety to the extentthat it is not inconsistent with the disclosure.

ADDITIONAL EMBODIMENTS

In certain embodiments, provided is a method for treating or preventinga vaso-occlusive crisis (VOC) in a subject suffering from sickle celldisease (SCD). A therapeutically effective amount of a compositioncomprising ADAMTS13 is administered to the subject. The subject may be ahuman patient with SCD, or an animal with SCD. The ADAMTS13 may be in arecombinant form. ADAMTS13 may be part of a formulation suitable forintravenous injection. ADAMTS13 may be part of a formulation suitablefor subcutaneous injection. The dosage of ADAMTS13 may be from 2,500IU/kg to 4,000 IU/kg, from 2,800 IU/kg to 3,800 IU/kg, from 3,000 IU/kgto 3,400 IU/kg, about 3,200 IU/kg, or 3,200 IU/kg in a rodent. Thedosage of ADAMTS13 may be from 40 IU/kg to 100 IU/kg, from 100 IU/kg to300 IU/kg, from 120 IU/kg to 240 IU/kg, from 150 IU/kg to 200 IU/kg, orfrom 300 IU/kg to 500 IU/kg in a human patient. The ADAMTS13 may beadministered intravenously at a time before, during or after an acuteVOC in a human patient, or an animal patient, having SCD. The ADAMTS13may be administered subcutaneously at a time before, during or after anacute VOC in a human patient, or an animal patient, having SCD. Thetreatment may be effective to protect the subject, e.g., a human patientor animal with SCD, from morbidity and mortality associated with VOC orhypoxia.

In certain embodiments, provided is a method for treating or preventingacute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Atherapeutically effective amount of a composition comprising ADAMTS13 isadministered to the subject. The ADAMTS13 may be in a recombinant form.ADAMTS13 may be part of a formulation suitable for intravenousinjection. ADAMTS13 may be part of a formulation suitable forsubcutaneous injection. The dosage of ADAMTS13 may be from 2,500 IU/kgto 4,000 IU/kg, from 2,800 IU/kg to 3,800 IU/kg, from 3,000 IU/kg to3,400 IU/kg, about 3,200 IU/kg, or 3,200 IU/kg in a rodent. The dosageof ADAMTS13 may be from 40 IU/kg to 100 IU/kg, from 100 IU/kg to 300IU/kg, from 120 IU/kg to 240 IU/kg, from 150 IU/kg to 200 IU/kg, or from300 IU/kg to 500 IU/kg in a human patient. The ADAMTS13 may beadministered intravenously at a time before, during or after an ALI orARDS in a human patient, or an animal patient. The ADAMTS13 may beadministered subcutaneously at a time before, during or after an ALI orARDS in a human patient, or an animal patient. The treatment may beeffective to protect the subject, e.g., a human patient or ALI and/orARDS, from morbidity and mortality.

In another embodiment, provided is a method for treating, ameliorating,or preventing (a) a VOC in a subject suffering from SCD or (b) a lunginjury in a subject suffering from or at risk of suffering from acutelung injury (ALI) and/or acute respiratory distress syndrome (ARDS). Atherapeutically effective amount of ADAMTS13 is administered to thesubject. The lung injury or vascular inflammation may be secondary to,or induced by, hypoxia. The lung injury or vascular inflammation may besecondary to, or induced by, reoxygenation stress. During hypoxia orreoxygenation stress, the level of oxygen may be about 7%, about 8%,about 9%, about 10%, 7-10%, or 7-9%. The subject may be a human patientwith SCD, a human patient experiencing a VOC, a human patient with anALI, a human patient with ARDS, an animal with SCD, an animalexperiencing VOC, an animal with ALI, an animal with ARDS, or an animalhomozygous for HbA. ADAMTS13 may be part of a formulation suitable forintravenous injection. ADAMTS13 may be part of a formulation suitablefor subcutaneous injection. The dosage of ADAMTS13 may be from 2,500IU/kg to 4,000 IU/kg, from 2,800 IU/kg to 3,800 IU/kg, from 3,000 IU/kgto 3,400 IU/kg, about 3,200 IU/kg, or 3,200 IU/kg in a rodent. Thedosage of ADAMTS13 may be from 40 IU/kg to 100 IU/kg, 100 IU/kg to 300IU/kg, from 120 IU/kg to 240 IU/kg, from 150 IU/kg to 200 IU/kg, or from300 IU/kg to 500 IU/kg in a human patient. The subject may be monitoredfor one or more of BAL protein content and BAL leukocyte count at one ormore times before, during, and after treatment. Administration ofADAMTS13 may be effective to decrease BAL protein content by at least35%, at least 36%, at least 37%, at least 38%, at least 39%, at least40%, 30-45%, 33-43%, 34-42%, 35-41%, or 36-40%, in comparison with acontrol (e.g., untreated subject). Administration of ADAMTS13 may beeffective to decrease BAL leukocyte count by at least 35%, at least 36%,at least 37%, at least 38%, at least 39%, at least 40%, 30-45%, 33-43%,34-42%, 35-41%, or 36-40%, in comparison with control (e.g., untreatedsubject).

In at least the above embodiments, administration of ADAMTS13 may beeffective to prevent activation or increased expression or level of atleast one of VCAM-1 and ICAM-1 and/or to reduce the expression of atleast one of ET-1, TXAS and HO-1. See, FIGS. 2B, 2C, and 3B.Administration of ADAMTS13 may be effective to decrease the expressionor level of TXAS or ET-1, as measured by densitometry for example, by atleast 65%, at least 68%, at least 71%, at least 74%, at least 77%, atleast 80%, 65-80%, 70-80%, or 70-75%, in comparison with a control(e.g., untreated subject). Administration of ADAMTS13 may be effectiveto decrease the expression or level or activity of ICAM-1, as measuredby densitometry for example, by at least 53%, at least 56%, at least59%, at least 62%, at least 65%, 53-65%, 55-62%, or 57-60%, incomparison with a control (e.g., untreated subject). Administration ofADAMTS13 may be effective to decrease the expression or level of HO-1,as measured by densitometry for example, by at least 46%, at least 47%,at least 48%, at least 49%, 46-49%, 47-49%, or 46-48%, in comparisonwith a control (e.g., untreated subject). Administration of ADAMTS13 maybe effective to decrease the ratio of P-NF-kB/NF-kB, as measured bydensitometry for example, by at least 63%, at least 67%, at least 71%,at least 75%, at least 79%, at least 83%, 63-83%, 67-79%, or 71-75%, incomparison with a control (e.g., untreated subject). In a subject withSCD or experiencing VOC, administration of ADAMTS13 may be effective todecrease the expression, level or activity of VCAM-1, as measured bydensitometry for example, by at least 40%, at least 42%, at least 44%,at least 46%, at least 48%, at least 50%, 40-50%, 42-48%, or 44-46%, incomparison with a control (e.g., untreated subject). In certainembodiments, the biomarker (e.g., VCAM-1, ICAM-1, P-NF-kB, NF-kB, ET-1,TXAS and HO-1) is measured in the lung. In certain embodiments, thebiomarker (e.g., VCAM-1, ICAM-1, P-NF-kB, NF-kB, ET-1, TXAS and HO-1) ismeasured in the kidney.

In at least the above embodiments, with respect to treating lung injuryor vascular inflammation associated with SCD, VOC, ALI, and/or ARDS,administration of ADAMTS13 may be effective to prevent activation orincreased expression or level of at least one of VCAM-1 and ICAM-1and/or to reduce the expression or level of at least one of ET-1, TXAS,and HO-1. See, FIGS. 2B and 2C. Administration of ADAMTS13 may beeffective to decrease the expression or level of TXAS or ET-1, asmeasured by densitometry for example, by at least 65%, at least 68%, atleast 71%, at least 74%, at least 77%, at least 80%, 65-80%, 70-80%, or70-75%, in comparison with a control (e.g., untreated subject).Administration of ADAMTS13 may be effective to decrease the expressionor level or activity of ICAM-1, as measured by densitometry for example,by at least 53%, at least 56%, at least 59%, at least 62%, at least 65%,53-65%, 55-62%, or 57-60%, in comparison with a control (e.g., untreatedsubject). Administration of ADAMTS13 may be effective to decrease theexpression or level of HO-1, as measured by densitometry for example, byat least 46%, at least 47%, at least 48%, at least 49%, 46-49%, 47-49%,or 46-48%, in comparison with a control (e.g., untreated subject).Administration of ADAMTS13 may be effective to decrease the ratio ofP-NF-kB/NF-kB, as measured by densitometry for example, by at least 63%,at least 67%, at least 71%, at least 75%, at least 79%, at least 83%,63-83%, 67-79%, or 71-75%, in comparison with a control (e.g., untreatedsubject). In a subject with SCD and/or experiencing a VOC,administration of ADAMTS13 may be effective to decrease the expressionnor level or activity of VCAM-1, as measured by densitometry forexample, by at least 40%, at least 42%, at least 44%, at least 46%, atleast 48%, at least 50%, 40-50%, 42-48%, or 44-46%, in comparison with acontrol (e.g., untreated subject). In certain embodiments, the biomarker(e.g., VCAM-1, ICAM-1, P-NF-kB, NF-kB, ET-1, TXAS and HO-1) is measuredin the lung.

In at least the above embodiments, with respect to treating kidneyinjury or vascular inflammation associated with SCD, VOC, ALI, and/orARDS, administration of ADAMTS13 may be effective to prevent activationand/or increased expression levels of VCAM-1, decrease the ratio ofP-NF-kB/NF-kB and/or to reduce the expression or level of at least oneof ET-1 or TXAS. See FIGS. 3A and 3B. Administration of ADAMTS13 may beeffective to decrease the expression nor level of TXAS, as measured bydensitometry for example, by at least 70%, at least 73%, at least 76%,at least 78%, at least 80%, at least 82%, 70-82%, 73-80%, or 76-78%, incomparison with a control (e.g., untreated subject). Administration ofADAMTS13 may be effective to decrease the ratio of P-NF-kB/NF-kB, asmeasured by densitometry for example, by at least 68%, at least 70%, atleast 72%, at least 75%, at least 78%, 68-78%, 70-75%, or 72-75%, incomparison with a control (e.g., untreated subject). Administration ofADAMTS13 may be effective to decrease the expression or level oractivity of VCAM-1 in a subject with SCD or experiencing VOC, asmeasured by densitometry for example, by at least 58%, at least 60%, atleast 62%, at least 64%, at least 67%, 58-67%, 60-64%, or 60-62%, incomparison with a control (e.g., untreated subject). In certainembodiments, the biomarker (e.g., VCAM-1, P-NF-kB, NF-kB, ET-1, TXAS andHO-1) is measured in the kidney.

In at least the above embodiments, a sample of blood from the subjectmay be taken, for example to monitor the treatment of SCD, VOC, ALI,and/or ARDS, with one or more of the following hematocrit valuesmeasured: % hematocrit (Hct) and mean corpuscular volume (MCV), asindicators of erythrocyte viability; hemoglobin (Hb), mean corpuscularhemoglobin (MCH), and cell hemoglobin concentration mean (CHCM), asindicators of oxygen binding capacity; heterogeneity of red celldistribution (HDW), as an indicator of presence of dense red cells;reticulocyte count (Retics), as an indicator of anemia status;neutrophil count, as an indicator of the systemic inflammatory status;and/or lactate dehydrogenase (LDH) as a general marker of cell damage.Administration of ADAMTS13 may be effective to decrease CHCM by at least5%, at least 5.5%, at least 6%, at least 6.5%, or at least 7%, incomparison with a control (e.g., untreated subject). Administration ofADAMTS13 may be effective to increase retics by at least 5%, at least7%, at least 9%, at least 11%, or at least 13%, in comparison with acontrol (e.g., untreated subject). Administration of ADAMTS13 may beeffective to decrease neutrophils (cells/microliter) by at least 30%, atleast 35%, at least 40%, at least 45%, or at least 50%, in comparisonwith a control (e.g., untreated subject). Administration of ADAMTS13 maybe effective to decrease LDH (cells/microliter) by at least 5%, at least10%, at least 15%, at least 20%, at least 25%, or at least 30%, incomparison with a control (e.g., untreated subject).

In at least the above embodiments, administration of ADAMTS13 insubjects with SCD or experiencing VOC administration of ADAMTS13 may beeffective to change levels of Hct %, Hb, MCV, MCH, and/or HDW.Administration of ADAMTS13 may be effective to increase Hct % insubjects with SCD or experiencing VOC by at least 60%, at least 65%, atleast 70%, at least 75%, at least 80%, or at least 85%, in comparisonwith a control (e.g., untreated subject). Administration of ADAMTS13 maybe effective to increase Hb in subjects with SCD or experiencing VOC byat least 18%, at least 20%, at least 22%, at least 24%, or at least 26%,in comparison with a control (e.g., untreated subject). Administrationof ADAMTS13 may be effective to increase MCV in subjects with SCD orexperiencing VOC by at least 18%, at least 20%, at least 22%, at least24%, or at least 26%, in comparison with a control (e.g., untreatedsubject). Administration of ADAMTS13 may be effective to increase MCH insubjects with SCD or experiencing VOC by at least 5%, at least 5.5%, atleast 6%, at least 6.5%, or at least 7%, in comparison with a control(e.g., untreated subject). Administration of ADAMTS13 may be effectiveto decrease HDW in subjects with SCD or experiencing VOC by at least12%, at least 14%, at least 16%, at least 18%, or at least 20%, incomparison with a control (e.g., untreated subject).

In at least the above embodiments, administration of ADAMTS13 insubjects with SCD experiencing VOC can reduce or prevent SCD relatedtissue injury. In certain embodiments, the tissue injury is cause byhypoxia. In certain embodiments, the tissue injury is caused byre-oxygenation. In certain embodiments, the tissue is lung tissue. Incertain embodiments, the tissue is kidney tissue. In certainembodiments, administration of ADAMTS13 reduced inflammatory cellinfiltrates and/or thrombi formation in the tissue as compared tocontrol. In certain embodiments, administration of ADAMTS13 reducedinflammatory cell infiltrates in the lung tissue as compared to control.In certain embodiments, ADAMTS13 administration decreases the lunginflammatory cell infiltrates by at least 20%, at least 30%, at least40%, at least 50%, or at least 60%. In certain embodiments,administration of ADAMTS13 reduced thrombi formation in the lung tissueas compared to control. In certain embodiments, ADAMTS13 administrationdecreases the lung thrombi formation by at least 20%, at least 30%, atleast 40%, at least 50%, at least 60%%, at least 70%, at least 75%, atleast 80%, or at least 85%. In certain embodiments, administration ofADAMTS13 reduced inflammatory cell infiltrates in the kidney tissue ascompared to control. In certain embodiments, ADAMTS13 administrationdecreases the kidney inflammatory cell infiltrates by at least 20%, atleast 30%, at least 40%, at least 50%, at least 60%, at least 70%, atleast 75%, at least 80%, at least 85%, at least 90%, at least 95%, atleast 97%, at least 98%, at least 99%, or at least 100%. In certainembodiments, administration of ADAMTS13 reduced thrombi formation in thelung tissue as compared to control. In certain embodiments, ADAMTS13administration decreases the lung thrombi formation by at least 20%, atleast 30%, at least 40%, at least 50%, or at least 60%.

In at least the above embodiments, administration of ADAMTS13 insubjects with ALI and/or ARDS can reduce or prevent ALR and/or ARDSrelated tissue injury. In certain embodiments, the tissue injury iscause by hypoxia. In certain embodiments, the tissue injury is caused byre-oxygenation. In certain embodiments, the tissue is lung tissue. Incertain embodiments, the tissue is kidney tissue. In certainembodiments, administration of ADAMTS13 reduced inflammatory cellinfiltrates and/or thrombi formation in the tissue as compared tocontrol. In certain embodiments, administration of ADAMTS13 reducedinflammatory cell infiltrates in the lung tissue as compared to control.In certain embodiments, ADAMTS13 administration decreases the lunginflammatory cell infiltrates by at least 20%, at least 30%, at least40%, at least 50%, or at least 60%. In certain embodiments,administration of ADAMTS13 reduced thrombi formation in the lung tissueas compared to control. In certain embodiments, ADAMTS13 administrationdecreases the lung thrombi formation by at least 20%, at least 30%, atleast 40%, or at least 50%. In certain embodiments, administration ofADAMTS13 reduced inflammatory cell infiltrates in the kidney tissue ascompared to control. In certain embodiments, ADAMTS13 administrationdecreases the kidney inflammatory cell infiltrates by at least 20%, atleast 30%, at least 40%, at least 50%, or at least 60%. In certainembodiments, administration of ADAMTS13 reduced thrombi formation in thelung tissue as compared to control. In certain embodiments, ADAMTS13administration decreases the lung thrombi formation by at least 20%, atleast 30%, or at least 40%.

It is understood that the examples and embodiments described herein arefor illustrative purposes only and that various modifications or changesin light thereof will be suggested to persons skilled in the art and areto be included within the spirit and purview of this application andscope of the appended claims.

EXAMPLES

Additional aspects and details of the disclosure will be apparent fromthe following examples, which are intended to be illustrative ratherthan limiting.

Example 1 ADAMTS13 Prevented the Death of SCD Mice Exposed to LethalHypoxia-Induced VOC

Because acute sickle cell events are triggered by low oxygen (hypoxia),this example was conducted to evaluate the impact of ADAMTS13 onsurvival in a model of SCD subject to hypoxia. The objective of thisexample was to determine if recombinant ADAMTS13 (rADAMTS13(BAX930/SHP655)) could protect humanized SCD mice exposed to lethalhypoxia-induced VOC. It has been shown previously that the exposition ofSCD mice to very severe, life-threatening hypoxia/reoxygenation stresscan be useful in evaluating the effectiveness of novel therapeutictreatments on the survival of SCD mice (Sabaa et al., JCI 118:1924,2008).

Experiments were performed on 4-6 week-old healthy control(Hba^(tm1(HBA)Tow) Hbb^(tm3(HBG1,HBB)Tow)) mice (i.e., AA) and SCD(Hba^(tm1(HBA)Tow) Hbb^(tm2(HBG1,HBB)*^()Tow)) mice (humanized mousemodel for sickle cell disease (i.e., SCD or SS mice)). Healthy (AA) andsickle cell disease mice (SCD or SS) were treated with either vehicle orrADAMTS13 at a dosage of 2,940 FRETS-U/kg (˜3,200 IU/kg) intravenously(iv), 1 hour before severe hypoxia/re-oxygenation stress (at about 7%oxygen for 10 hours), followed by 3 hours of re-oxygenation with about21% oxygen), which previously has been shown to biologicallyrecapitulate the organ damage observed in acute VOC in human SCDpatients. See similar protocol as reported by Kalish et al. (supra).More specifically, four groups (n=6) of AA and SCD mice were treatedwith either vehicle or ADAMTS13 (BAX930/SHP655) (2,940 FRETS-U/kg(˜3,200 IU/kg)) and were exposed to conditions of hypoxic stress.

Recombinant ADAMTS13 treatment completely protected SCD mice from deathas compared to SCD mice treated with vehicle (0% mortality in rADAMTS13treated SCD vs. 83.3% mortality in vehicle-treated SCD mice at 10 hourshypoxia; 0% mortality in rADAMTS13-treated SCD vs. 100% mortality invehicle-treated SCD mice at 10 hours hypoxia followed by 3 hoursre-oxygenation; p<0.001) (FIG. 1). No differences in mouse survival wereobserved in healthy mice treated with either vehicle or rADAMTS13.

The data demonstrated that ADAMTS13 had a protective effect, includingincreased survival, in a model of SCD after exposure to hypoxic stress.

Example 2 ADAMTS13 Reduces Hypoxia/Reoxygenation Stress-InducedAbnormalities in the Lung

The objective of this example was to evaluate the impact of ADAMTS13 onlung injury and vascular inflammation induced by hypoxia/reoxygenation(H/R) stress.

Healthy control (Hba^(tm1(HBA)Tow) Hbb^(tm3(HBG1,HBB)Tow)) and SCD(Hba^(tm1(HBA)Tow) Hbb^(tm2(HBG1,HBB)*^()Tow)) mice were exposed tohypoxia/re-oxygenation (H/R) stress, which previously were shown tobiologically recapitulate the acute VOC and the organ damage observed inacute VOC in human SCD patients. In particular, six experimental groupswere used—(1) AA untreated normoxia; (2) SS untreated normoxia; (3) AAvehicle plus H/R; (4) AA ADAMTS13 (BAX930/SHP655) plus H/R; (5) SSvehicle plus H/R; and (6) SS ADAMTS13 (BAX930/SHP655) plus H/R. In thisexperiment, H/R conditions were 8% oxygen for 10 h followed by 3 hrecovery at about 21% oxygen, an experimental scheme usually not fatalfor SCD mice (Kalish et al., Haematologica 100:870-80, 2015).

Under both normoxic and H/R conditions, pulmonary vascular leakage wasevaluated in mice by measuring protein content and leukocyte counts(total leukocytes measured in cells/microliter) in bronchoalveolarlavage fluid (BAL).

Pulmonary vascular leakage was examined by measuring protein content andleukocyte counts (i.e., cell number) in bronchoalveolar lavage fluid(BAL). As shown in Table 1, under normoxic conditions, increased BALprotein level and leukocyte cell numbers were detected in SCD micecompared to healthy mice, indicating the accumulation of proteins andinflammatory cells in the alveolar space. Interestingly, in response toH/R, both BAL protein and leukocyte counts were significantly increasedin both SCD and AA mice.

TABLE 1 Results of pulmonary leakage experiments carried out in AA andSCD mice under both normoxic and hypoxic conditions. Normoxic conditionsHypoxic condition (8% oxygen) AA mice SCD mice AA mice AA mice SCD miceSCD mice untreated untreated Vehicle BAX930 Vehicle BAX930 (n = 6) (n =6) (n = 6) (n = 6) (n = 6) (n = 6) BAL protein 0.9 ± 0.03 2.5 ± 0.05°3.1 ± 0.04 1.8 ± 0.05* 5.33 ± 0.4° 3.4 ± 0.07* content (mg/mL) BAL 200 ±40  832 ± 36°  567 ± 20  328 ± 12*  1977 ± 54°  1198 ± 22*   leukocytes(cells/μL) AA: Hb A homozygous control mice or healthy mice; SCD: HbShomozygous mice or sickle cell mice; and BAL: Bronchoalveolar lavage; *P< 0.05 compared to vehicle-treated mice; °P < 0.05 compared to AA mice.

The data showed that SCD mice had a significant increase in peripheralneutrophils (cells/microliter) compared to AA mice; however, treatmentwith ADAMTS13 significantly reduced the neutrophil count. The data alsoshowed that SCD mice had a greater number of leukocytes (bronchoalveolarlavage (BAL) total leukocytes (cells/microliter)) and greater leukocyteprotein content (BAL protein (mg/mL) in bronchoalveolar lavage) comparedto controls, indicating that the SCD mice suffered vascular leakage.Treatment with ADAMTS13 markedly reduced this effect (FIG. 2A and Table1), indicating that ADAMTS13 reduced systemic inflammation and reducedabnormalities in pulmonary vascular dysfunction.

These data indicate that ADAMTS13 prevented the hypoxia-inducedinflammatory vasculopathy and abnormalities of pulmonary vascularleakage in lungs from SCD mice during acute vaso-occlusive crisis.Moreover, ADAMTS13 significantly decreased both BAL protein content andleukocyte cell number in both SCD and AA mice compared tovehicle-treated controls, indicating that ADAMTS13 had a protectiveeffect on the lung under hypoxic conditions.

Example 3 ADAMTS13 Reduced Hypoxia/Reoxygenation Stress-Induced LungVascular Activation

In order to study the effects of ADAMTS13 on injury and vascularinflammation in the lung, additional experiments were conducted with thesame six experimental groups, as described in Example 2 (i.e., (1) AAuntreated normoxia; (2) SS untreated normoxia; (3) AA vehicle plus H/R;(4) AA ADAMTS13 (BAX930/SHP655) plus H/R; (5) SS vehicle plus FUR; and(6) SS ADAMTS13 (BAX930/SHP655) plus H/R). In this example, like thatreported in Example 2, animals were administered vehicle or ADAMTS13 andthen exposed to 8% oxygen for 10 h followed by 3 h recovery at 21%oxygen. Additional controls (AA and SCD) were also subjected toconditions of normoxia without vehicle or ADAMTS13.

Immunoblot analyses with specific antibodies against various markers ofinflammation, vaso-constriction and platelet aggregation (i.e., nuclearfactor kappa B (NF-kB), endothelin-1 (ET-1), heme-oxygenase 1 (HO-1),intercellular adhesion molecule 1 (ICAM-1), thromboxane synthase (TXAS),and vascular cell adhesion molecule 1 (VCAM-1)) were carried out tomeasure the expression of these proteins in the lungs of healthy control(AA) and SCD mice treated with either vehicle or rADAMTS13 afterexposure to hypoxic (e.g., H/R) or normoxic conditions.

The data from this example showed that ADAMTS13 prevented thehypoxia-induced activation of NF-kB in lung tissues from AA and SCDmice, indicating that ADAMTS13 decreases the pulmonary inflammationprocess triggered by hypoxia (FIG. 2B). In lungs from SCD mice underhypoxia, ADAMTS13 prevented activation of VCAM-1 and ICAM-1, markers ofvascular activation and inflammatory vasculopathy, and reduced theexpression of endothelin-1 (ET-1), thromboxane synthase (TXAS), andheme-oxygenase-1 (HO-1) (FIG. 2C).

Table 2 reports the densitometric values obtained through immunoblotanalyses with specific antibodies against nuclear factor kappa B (NF-kB)and its activated form (P-NF-kB), endothelin 1 (ET-1), heme-oxygenase 1(HO-1), intercellular adhesion molecule 1 (ICAM-1), thromboxane synthase(TXAS), and vascular cell adhesion molecule 1 (VCAM-1) in the lungs fromhealthy control (AA) and sickle cell (SCD) mice treated with eithervehicle or rADAMTS13 and exposed to normoxic or hypoxia/reoxygenationstress.

As set out in Table 2, under normoxic conditions, all of the measuredprotein markers (except for ICAM-1) showed increased protein expressionin SCD mice compared to AA mice. Under hypoxic conditions, there wasfurther increased expression of all the measured markers in both healthycontrols and SCD mice. However, treatment with ADAMTS13 (i.e.,BAX930/SHP655) had a protective effect in both AA and SCD mice, asdemonstrated by lower levels of all markers of inflammation,vaso-constriction and platelet aggregation tested.

TABLE 2 Normoxic conditions Hypoxic condition (8% oxygen) AA mice SCDmice AA mice AA mice SCD mice SCD mice untreated untreated VehicleBAX930 Vehicle BAX930 (n = 6) (n = 6) (n = 6) (n = 6) (n = 6) (n = 6)TXAS 0.9 ± 0.09   2 ± 0.025° 2.4 ± 0.05 0.7 ± 0.04* 3.7 ± 0.05°  0.8 ±0.034* (DU) ET-1 0.55 ± 0.06  1.65 ± 0.07°   1.7 ± 0.025  0.4 ± 0.042* 2 ± 0.06° 0.6 ± 0.03* (DU) VCAM-1 0.5 ± 0.03 1.4 ± 0.07° 2.1 ± 0.04 2.0± 0.02  3.2 ± 0.09° 1.8 ± 0.03* (DU) ICAM-1 0.8 ± 0.03 0.9 ± 0.07   1.7± 0.045 0.75 ± 0.04*   2.3 ± 0.081° 0.85 ± 0.07*  (DU) HO-1 0.4 ± 0.061.1 ± 0.03° 2.8 ± 0.02 1.5 ± 0.07* 3.0 ± 0.04  1.44 ± 0.09*  (DU)P-NF-kB/ 0.8 ± 0.03 1.6 ± 0.08°  2 ± 0.6 0.7 ± 0.05* 3.8 ± 0.34° 0.6 ±0.03* NF-kB ratio (DU) AA: Hb A homozygous control mice or healthy mice;SCD: HbS homozygous mice or sickle cell mice; TXAS: Thromboxanesynthase; ET-1: Endothelin 1; VCAM-1: Vascular Cell Adhesion Molecule 1;ICAM-1: Intercellular Adhesion Molecule 1; HO-1: Heme-oxygenase 1;P-NF-kB: Phospho-Nuclear Factor kappa B; and NF-kB: Nuclear Factor kappaB. *P < 0.05 compared to vehicle-treated mice; °P < 0.05 compared to AAmice.

Recombinant ADAMTS13 markedly reduced the expression levels of each ofthe protein markers tested in SCD mice (i.e., compared tovehicle-treated SCD mice) (Table 2). Furthermore, recombinant ADAMTS13reduced lung expression of all the protein markers tested, with theexception of VCAM-1, in healthy control (AA) mice (i.e., compared tovehicle-treated control mice).

These data indicate that ADAMTS13 prevented the hypoxia-inducedinflammatory vasculopathy and abnormalities of pulmonary vascularleakage in lungs from SCD mice during acute vaso-occlusive crisis. Inaddition, ADAMTS13 prevented the hypoxia induced increased expression ofpotent modulators of vascular tone, such as ET-1 and TXAS, bothindicated as factors contributing to vascular dysfunction described inSCD during acute events. Moreover, the data also showed that ADAMTS13had a protective effect on lung tissue in healthy animals subject tohypoxic conditions. Thus, the data indicate that ADAMTS13 reducesvascular activation and inflammatory responses related to hypoxic stressin the lungs of SCD and healthy mice.

Example 4 ADAMTS13 Reduces Hypoxia/Reoxygenation Stress-Induced KidneyVascular Activation

In order to study the effects of ADAMTS13 on injury and vascularinflammation in the kidney, additional experiments were conducted withthe same six experimental groups, as described in Example 2 (i.e., (1)AA untreated normoxia; (2) SS untreated normoxia; (3) AA vehicle plusH/R; (4) AA ADAMTS13 (BAX930/SHP655) plus H/R; (5) SS vehicle plus FUR;and (6) SS ADAMTS13 (BAX930/SHP655) plus H/R). In this example, likethose reported in Examples 2 and 3, animals were administered vehicle orADAMTS13 and then exposed to 8% oxygen for 10 h followed by 3 h recoveryat about 21% oxygen, which was previously shown to biologicallyrecapitulate the acute VOC and the organ damage observed in acute VOC inhuman SCD patients. Additional controls (AA and SCD) were also subjectedto conditions of normoxia without vehicle or ADAMTS13.

Immunoblot analyses with specific antibodies against NF-kB and itsactivated form, P-NF-kB, as well as ET-1, TXAS, and VCAM-1 were carriedout to measure the expression of these proteins in the kidneys from AAand SCD mice treated with either vehicle or rADAMTS13.

Table 3 reports the densitometric values obtained through immunoblotanalyses with specific antibodies against nuclear actor kappa B (NF-kB)and its activated form (P-NF-kB), endothelin 1 (ET-1), thromboxanesynthase (TXAS), and vascular cell adhesion molecule 1 (VCAM-1) in thekidneys from healthy control (AA) and sickle cell (SCD) mice treatedwith either vehicle or rADAMTS13 and exposed to normoxic or hypoxic(hypoxia/reoxygenation stress) conditions. As can be observed in Table3, under normoxic conditions, all protein marker levels were greater inSCD mice than in AA mice. Under hypoxic conditions, the expressionlevels of all protein markers, except VCAM-1, were further increased inboth SCD and AA mice.

TABLE 3 Normoxic conditions Hypoxic condition (8% oxygen) AA mice SCDmice AA mice AA mice SCD mice SCD mice untreated untreated VehicleBAX930 Vehicle BAX930 (n = 6) (n = 6) (n = 6) (n = 6) (n = 6) (n = 6)TXAS 0.6 ± 0.05 0.97 ± 0.03° 1.8 ± 0.07 0.4 ± 0.022*  2.5 ± 0.041° 0.6 ±0.02* (DU) ET-1  0.5 ± 0.051 0.98 ± 0.05°  1.1 ± 0.012 0.99 ± 0.02   1.5± 0.03° 1.4 ± 0.02  (DU) VCAM-1 1.1 ± 0.02  1.9 ± 0.06° 1.05 ± 0.08  0.9± 0.05  2.1 ± 0.08° 0.8 ± 0.03* (DU) P-NF-kB/ 0.4 ± 0.02  1.5 ± 0.045°2.4 ± 0.08 0.6 ± 0.055*  2.3 ± 0.023 0.7 ± 0.08* NF-kB ratio (DU) AA: HbA homozygous control mice or healthy mice; SCD: HbS homozygous mice orsickle cell mice; TXAS: Thromboxane synthase; ET-1: Endothelin 1;VCAM-1: Vascular Cell Adhesion Molecule 1; P-NF-kB: Phospho-NuclearFactor kappa B; and NF-kB: Nuclear Factor kappa B. *P < 0.05 compared tovehicle-treated mice; °P < 0.05 compared to AA mice.

The data from this example showed that ADAMTS13 prevented thehypoxia-induced activation of NF-kB in the kidneys from AA and SCD mice,as well as of SCD mice under normoxic conditions (Table 3 and FIG. 3A).In hypoxia-exposed SCD mice, there was increased expression of VCAM-1,ET-1, and TXAS. ADAMTS13 prevented the hypoxia-induced increasedexpression of VCAM-1 and TXAS in kidneys of both mouse strains and ofET-1 levels in kidneys from AA mice (Table 3 and FIG. 3B).

These data indicate that ADAMTS13 prevented the hypoxia-inducedincreased expression of potent modulators of vascular tone, and/orfactors contributing to vascular dysfunction described in SCD duringacute events. The data indicate that ADAMTS13 reduces vascularactivation and inflammatory responses related to hypoxic stress in thekidneys of SCD and healthy mice. The example showed that rADAMTS13 couldreduce acute sickle cell related events, like vaso-constriction andinflammatory vasculopathy in the kidney.

Example 5 ADAMTS13 Ameliorates Hypoxia/Reoxygenation Stress-InducedAbnormalities in Various Hematology Parameters

In order to study the effects of ADAMTS13 on various hematologyparameters, additional experiments were conducted with the same sixexperimental groups, as described in Example 2 (i.e., (1) AA untreatednormoxia; (2) SS untreated normoxia; (3) AA vehicle plus H/R; (4) AAADAMTS13 (BAX930/SHP655) plus H/R; (5) SS vehicle plus H/R; and (6) SSADAMTS13 (BAX930/SHP655) plus H/R). In this example, like those reportedin Examples 2-4, animals were administered vehicle or ADAMTS13 and thenexposed to conditions of normoxia or H/R (8% oxygen for 10 h followed by3 h recovery at about 21% oxygen).

The following hematology parameters were determined: % hematocrit (Hct)and mean corpuscular volume (MCV), as indicators of erythrocyteviability; hemoglobin (Hb), mean corpuscular hemoglobin (MCH), and cellhemoglobin concentration mean (CHCM), as indicators of oxygen bindingcapacity; heterogeneity of red cell distribution (HDW), as an indicatorof presence of dense red cells; reticulocyte count, as an indicator ofanemia status; neutrophil count, as an indicator of the systemicinflammatory status; and lactate dehydrogenase (LDH) as a general markerof cell damage.

Hematocrit is the ratio of the volume of red blood cells to the totalvolume of blood. MCV is the average volume of RBCs. Hemoglobin is theprotein responsible for transporting oxygen in the blood, and MCH is theaverage amount of hemoglobin per RBC in a blood sample; CHCM reflectsthe hemoglobin content within intact RBCs. Hemoglobin distribution width(HDW) is a measurement of the heterogeneity of the red cell hemoglobinconcentration. Reticulocytes are newly produced, relatively immature redblood cells; reticulocyte count indicates whether enough red blood cellsare being produced in the bone marrow. Neutrophils are recruited to thesite of injury within minutes following a trauma; thus, neutrophils arethe hallmark of acute inflammation and neutrophil count indicatesinflammatory status.

Table 4 shows the hematological parameters in healthy control (AA) andsickle cell (SCD) mice in normoxic conditions and after treatment withADAMTS13 (i.e., BAX930/SHP655) or vehicle and exposure tohypoxia/reoxygenation stress. As shown in Table 4, under normoxicconditions, Hct and Hb levels were lower, while MCV and HDW levels werehigher, as were reticulocyte number and neutrophil number, in SCD micecompared to control (AA) mice. In healthy control mice, hypoxicconditions increased the number of reticulocytes and neutrophils. Theadministration of ADAMTS13 to control mice ameliorated the largeincrease in neutrophil number, indicating a reduction in inflammation.In SCD mice, hypoxic conditions reduced Hct, Hb, MCV and MCH, andincreased CHCM, HDW, and neutrophil number. The administration ofADAMTS13 to SCD mice ameliorated the decrease in Hct, Hb, MCV, and MCH,and ameliorated the increase in CHCM, HDW, and neutrophil number.

TABLE 4 Normoxic conditions Hypoxic condition (8% oxygen) AA mice SCDmice AA mice AA mice SCD mice SCD mice untreated untreated VehicleBAX930 Vehicle BAX930 (n = 6) (n = 6) (n = 6) (n = 5) (n = 6) (n = 5)Hct  46.3 ± 0.95 35.6 ± 1.6° 45.3 ± 0.8 44.3 ± 0.4 15.8 ± 2.3° 27.9 ±0.8* (%) Hb 13.8 ± 1.3  8.7 ± 0.51° 13.4 ± 0.1 13.1 ± 0.5 5.99 ± 0.5° 7.4 ± 0.5* (g/dL) MCV 37.9 ± 0.2 50.9 ± 1.8° 38.3 ± 0.3 38.5 ± 0.3 41.3± 1.7° 51.2 ± 1.8* (fL) MCH 12.0 ± 0.5 11.8 ± 1.2  12.0 ± 0.4 11.2 ± 0.2 9.1 ± 0.2° 9.7 ± 0.4 (g/dL) CHCM 25.2 ± 0.1 25.1 ± 0.4  25.1 ± 0.6 23.3± 0.9 26.8 ± 0.3° 24.8 ± 0.2* (g/dL) HDW  2.88. ± 0.03  4.72 ± 0.08° 2.86 ± 0.03  2.9 ± 0.04  5.63 ± 0.06°  4.78 ± 0.04* (g/dL) Retics 7.22± 0.5 43.1 ± 11°  8.59 ± 0.7  9.6 ± 0.21 42.1 ± 12°   45 ± 2.9 (%)Neutrophils  841 ± 135 3251 ± 488° 3600 ± 120  1768 ± 299* 6800 ± 250°4399 ± 133* (cells/μL) LDH (U/L) 288 ± 12 573 ± 30° 293 ± 15 277 ± 261234 ± 81°  852 ± 19* AA: Hb A homozygous control mice or healthy mice;SCD: HbS homozygous mice or sickle cell mice; Hct: hematocrit; Hb:hemoglobin; MCV: mean corpuscular volume; MCH: mean corpuscularhemoglobin; CHCM: cell hemoglobin concentration; HDW: heterogeneity ofred cell distribution; Retics: reticulocytes; and LDH: lactatedehydrogenase. *P < 0.002 compared to vehicle-treated mice; °P < 0.005compared to AA mice.

Example 6 ADAMTS13 Ameliorates Hypoxia/Reoxygenation Stress-InducedAbnormalities in Various Histopathology Parameters

In order to study the effects of ADAMTS13 on various histopathologyparameters, additional experiments were conducted with four experimentalgroups—(1) AA vehicle plus H/R; (2) AA ADAMTS13 (BAX930/SHP655) plusH/R; (3) SS vehicle plus H/R; and (4) SS ADAMTS13 (BAX930/SHP655) plusH/R). In this example, animals were administered vehicle or ADAMTS13 andthen exposed to conditions of H/R (8% oxygen for 10 h followed by 3 hrecovery at about 21% oxygen).

Lungs and kidneys were collected following the 3 h re-oxygenation. Thelung and kidney pathology was analyzed and the inflammatory cellinfiltrate and presence of thrombi were determined.

The histologic analysis revealed that H/R stress induced a severe SCDrelated tissue injury in both lung and kidney of SCD mice. In the lung,H/R induced inflammatory cell infiltration and thrombi formation in allSCD mice (Table 5). In AA mice, H/R induced modest inflammatory cellinfiltration and some thrombi formation in few mice. In SCD mice,ADAMTS13 (BAX930/SHP655) reduced inflammatory cell infiltrate andthrombi formation compared to vehicle treated SCD mice. In AA mice,ADAMTS13 (BAX930/SHP655) reduced the cell inflammatory infiltrate in thelung.

In the kidney, H/R induced inflammatory cell infiltration and thrombi inall SCD mice. In AA mice, H/R induced limited inflammatory cellinfiltration with few thrombi formation in a small number of mice.ADAMTS13 (BAX930/SHP655) reduced inflammatory cell infiltrates in kidneyfrom H/R exposed SCD mice, impacting also the thrombi formation. In AAmice, ADAMTS13 (BAX930/SHP655) reduced cell inflammatory infiltrateswith no effects on thrombi formation (Table 5).

TABLE 5 AA mice SCD mice H/R H/R H/R H/R vehicle BAX930 vehicle BAX930Lung (n = 5) (n = 5) (n = 5) (n = 4) Inflammatory +(4/5) +(2/5) +(2/5)+(1/4) cell infiltrates ++(3/5) Thrombi +(2/5) +(5/5) +(5/5) +(1/4) 2.5per 2.2 3 per 3 per field of field of field of field of observationobservation observation observation Kidney (n = 5) (n = 5) (n = 5) (n =4) Inflammatory +(2/5) +(1/5) +(2/5) 0 cell infiltrates ++(1/5) Thrombi+(4/5) +(5/5) +(5/5) +(4/4) 3.8 per 3.2 per 5 per 2.5 per field of fieldof field of field of observation observation observation observationH/R: hypoxia/re-oxygenation stress; presence of thrombi per field of250× magnification given in numbers; presence of inflammatory cellinfiltrates per field of magnification (250× for lung tissue, 400× forkidneys): + 1-10 cells per field of magnification; ++ 10-50 cells perfield of magnification; number of animals with findings stated inparentheses

Example 7 ADAMTS13 Reduces Organ Damage in Subjects Suffering fromHypoxemia and in Subjects at Risk of Developing ARDS

ADAMTS13 has been demonstrated to reduce end organ injury in a mousemodel of severe hypoxemia (8% oxygen for 10 h followed by 3 h recoveryat about 21% oxygen). Because severe hypoxemia injury is a contributingfactor to the pathophysiology observed in patients suffering from acutelung injury (ALI) and acute respiratory distress syndrome (ARDS)(ALI/ARDS), it was hypothesized that the administration of ADAMTS13 topatients either at risk for or who have developed ALI and/or ARDS(ALI/ARDS) could prevent, treat or ameliorate the disease process andresult in improved outcomes such as survival, long term lung function,and avoidance of other end organ injury.

Mice are administered LPS, either directly to the lungs throughintratracheal injection or inhalation, or intraperitoneally orintravenously to incite a systemic inflammatory response. Mice treatedwith intratracheal LPS have an acute and robust inflammatory cell influxto the lung with resolution by 48 hours. Intraperitoneal LPS activatessystemic inflammation and is associated with a mild lung injury. Thisinjury can be augmented with either repeated injections of LPS or theimplantation of an LPS pump in the peritoneal cavity to continuallyrelease LPS for hours, or even days.

ADAMTS13 is administered in doses of about 50, 100, 200, 500, 1,000,2,000, and 3,000 international units per kilogram body weight prior totreatment with LPS and within 12, 24, 48, 72, and 96 hours aftertreatment with LPS. Doses of ADAMTS13 are administered daily or every 12hours subcutaneously or intravenously until subjects are sacrificed toexamine inflammatory response in the lung and organ damage.

ADAMTS13 treatment reduces the inflammatory response, includinginflammatory cell influx to the lungs, as measured by the reduced numberof neutrophils, macrophages, monocytes, mast cells, eosinophils, and/orbasophils, present in the lungs of mice treated with ADAMTS13. ADAMTS13treatment also reduces organ damage, as measured by blood urea nitrogen(BUN), creatinine, BUN/creatinine ratio, troponin, neuron-specificenolase (NSE).

The invention has been described in terms of particular embodimentsfound or proposed to comprise specific modes for the practice of theinvention. Various modifications and variations of the describedinvention will be apparent to those skilled in the art without departingfrom the scope and spirit of the invention. Although the invention hasbeen described in connection with specific embodiments, it should beunderstood that the invention as claimed should not be unduly limited tosuch specific embodiments. Indeed, various modifications of thedescribed modes for carrying out the invention that are obvious to thoseskilled in the relevant fields are intended to be within the scope ofthe following claims.

1.-26. (canceled)
 27. A method for treating, ameliorating, or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS), the method comprising administering to the subject in need thereof a therapeutically effective amount of a composition comprising A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13).
 28. The method of claim 27, wherein the subject suffers from a condition or a combination of the conditions selected from the group consisting of inflammatory pulmonary edema, inflammatory pulmonary infiltrates, impaired oxygenation, and hypoxemia.
 29. The method of claim 27, wherein administering ADAMTS13 results in at least one of improved survival, improved lung function, reduced organ damage, reduced pulmonary vascular leakage, or a combination of any thereof as compared to control or without treatment.
 30. The method of claim 27, wherein administering ADAMTS13 reduces at least one of inflammation, vasoconstriction, platelet aggregation, or a combination of any thereof as compared to control or without treatment.
 31. The method of claim 27 wherein administering ADAMTS13 reduces and/or prevents at least one of impaired blood flow, blood coagulation, vascular inflammation, thrombosis, ischemic cell damage, organ damage, or a combination of any thereof as compared to control or without treatment.
 32. The method of claim 27, wherein administering ADAMTS13 reduces and/or prevents pain or severity of the pain as compared to control or without treatment.
 33. The method of claim 27, wherein administering ADAMTS13 reduces the frequency of occurrence of ALI and/or ARDS and/or duration of ALI and/or ARDS episodes as compared to without treatment.
 34. The method of claim 27, wherein administering ADAMTS13 reduces expression, level, and/or activation of at least one of VCAM-1, ICAM-1, P-NF-kB, NF-kB, ET-1, TXAS, and HO-1 in an organ as compared to control or without treatment.
 35. The method of claim 27, wherein administering ADAMTS13 increases the level of at least one of Hct, Hb, MCV, and MCH in the blood as compared to control or without treatment.
 36. The method of claim 27, wherein administering ADAMTS13 reduced the level of at least one of CHCM, HDW, LDH, and neutrophil numbers in the blood as compared to control or without treatment.
 37. The method of claim 27, wherein the therapeutically effective amount of ADAMTS13 is from about 20 to about 6,000 international units per kilogram body weight, about 40 to about 4,000 international units per kilogram body weight, about 100 to about 3,000 international units per kilogram body weight, or about 50 to about 500 international units per kilogram body weight. 38.-40. (canceled)
 41. The method of claim 27, wherein the composition comprising ADAMTS13 is administered in a single bolus injection, monthly, every two weeks, weekly, twice a week, every other day, daily, every 12 hours, every eight hours, every six hours, every four hours, or every two hours.
 42. The method of claim 27, wherein the composition comprising ADAMTS13 is administered intravenously or subcutaneously.
 43. The method of claim 27, wherein the ADAMTS13 is recombinant ADAMTS13.
 44. The method of claim 27, wherein the ADAMTS13 is plasma derived.
 45. The method of claim 27, wherein the subject is a mammal.
 46. The method of claim 27, wherein the subject is a human.
 47. The method of claim 27, wherein the composition is in a stable aqueous solution ready for administration.
 48. The method of claim 27, wherein the therapeutically effective amount of the composition comprising ADAMTS13 is administered to the subject within 48 hours after the detection of inflammatory pulmonary edema, inflammatory pulmonary infiltrates, impaired oxygenation, or hypoxemia.
 49. The method of claim 27, wherein the therapeutically effective amount of the composition comprising ADAMTS13 for treating, ameliorating, or preventing lung injury is sufficient to maintain an effective circulating level of ADAMTS13 activity in the subject. 50.-51. (canceled) 